bion_10q.htm

0001477932-23-003193.txt : 20230509 0001477932-23-003193.hdr.sgml : 20230509 20230509113948 ACCESSION NUMBER: 0001477932-23-003193 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230509 DATE AS OF CHANGE: 20230509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNexus Gene Lab Corp CENTRAL INDEX KEY: 0001737523 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 262124961 STATE OF INCORPORATION: WY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-229399 FILM NUMBER: 23900868 BUSINESS ADDRESS: STREET 1: 10-2 TOWER B, VERTICAL BUSINESS SUITE, STREET 2: 8 JALAN KERINCHI, CITY: KUALA LUMPUR STATE: N8 ZIP: 59200 BUSINESS PHONE: 60122126512 MAIL ADDRESS: STREET 1: 10-2 TOWER B, VERTICAL BUSINESS SUITE, STREET 2: 8 JALAN KERINCHI, CITY: KUALA LUMPUR STATE: N8 ZIP: 59200 FORMER COMPANY: FORMER CONFORMED NAME: BioNexus Gene Lab Coporation DATE OF NAME CHANGE: 20180413 10-Q 1 bion_10q.htm FORM 10-Q bion_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

☐	TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________

Commission File Number: 333-229399

BIONEXUS GENE LAB CORP.

(Exact name of registrant as specified in its charter)

Wyoming		35-2604830
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

Unit 02, Level 10 Tower B, Avenue 3, The Vertical Business Suite II Bangsar South No. 8 Jalan Kerinchi Kuala Lumpur, Malaysia		59200
(Address of Principal Executive Offices)		(Zip Code)

+60 1221-26512

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer, “ “ accelerated filer, “ “non-accelerated filer ,” “ smaller reporting company, “ and “ emerging growth company “ in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of March 31, 2023, the aggregate market value of shares held by non-affiliates of the registrant was approximately $48,487,449.

As of the date of this filing, there were 173,718,152 shares of common stock, no par value per share, issued and outstanding.

TABLE OF CONTENTS

		Page
PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4.	Controls and Procedures	27

PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	28
Item 2.	Unregistered Sale of Equity Securities and Use of Proceeds	28
Item 3.	Defaults Upon Senior Securities	28
Item 4.	Mine Safety Disclosures	28
Item 5.	Other Information	28
Item 6.	Exhibits	29

SIGNATURES		30

Table of Contents

CAUTIONARY NOTE REGARDING

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains statements that may be deemed to be “forward-looking statements” within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations and or future financial performance. In some cases, you can identify forward-looking statements by their use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “ought to,” “plan,” “possible,” “potentially,” “predicts,” “project,” “should,” “will,” “would,” negatives of such terms or other similar terms. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The forward-looking statements in this Quarterly Report on Form 10-Q include, without limitation, statements relating to:

	●	our goals and strategies;

	●	our future business development, results of operations and financial condition;

	●	our estimates regarding expenses, future revenues, capital requirements and our need for additional financing;

	●	our estimates regarding the market opportunity for our services;

	●	the impact of government laws and regulations;

	●	our ability to recruit and retain qualified personnel;

	●	our failure to comply with regulatory guidelines;

	●	uncertainty in industry demand;

	●	general economic conditions and market conditions in the financial services industry;

	●	future sales of large blocks or our securities, which may adversely impact our share price; and

	●	depth of the trading market in our securities.

The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including those described in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and elsewhere in this Quarterly Report on Form 10-Q.

You should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q, to conform these statements to actual results or to changes in our expectations.

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. Financial Statements

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF MARCH 31, 2023 AND DECEMBER 31, 2022

(Currency expressed in United States Dollars (“US$”))

			As of
			March 31,			December 31,
	Note		2023			2022
			(Unaudited)			(Audited)
ASSETS
CURRENT ASSETS
Cash and bank balances				406,787			611,849
Fixed deposits placed with financial institutions				1,566,425			1,507,015
Trade receivables		3		2,528,746			2,868,364
Other receivables, deposits and prepayments				29,346			25,240
Tax recoverable		4		27,823			31,551
Inventories				899,636			977,807
Total current assets				5,458,763			6,021,826

NON-CURRENT ASSETS
Operating lease right of use assets		5		51,436			55,730
Property, plant and equipment, net		6		1,481,767			1,511,708
Other investments		7		1,194,675			1,150,898
Total non-current assets				2,727,878			2,718,336
TOTAL ASSETS			$	8,186,641		$	8,740,162

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Trade payables		8		1,493,774			1,861,015
Other payables and accrued liabilities				37,550			103,370
Current portion of operating lease liabilities		5		16,733			16,569
Advance payment from customer				15,322			23,123
Total current liabilities				1,563,379			2,004,077

NON-CURRENT LIABILITIES
Non-current portion of operating lease liabilities		5		35,676			40,206
Deferred tax liabilities		4		30,678			30,866
Total non-current liabilities				66,354			71,072
TOTAL LIABILITIES			$	1,629,733		$	2,075,149

STOCKHOLDERS’ EQUITY
As at March 31, 2023, common stock, no par value; 300,000,000 shares authorized and 173,718,152 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2022, common stock, no par value; 300,000,000 shares authorized and 173,718,152 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding.		10		10,929,574			10,779,574
Additional paid in capital				(5,011,891	)		(5,011,891	)
Accumulated surplus				1,087,326			1,156,392
Accumulated other comprehensive losses				(448,101	)		(409,062	)
TOTAL STOCKHOLDERS’ EQUITY				6,556,908			6,665,013

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY			$	8,186,641		$	8,740,162

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

	Three months ended
	March 31,
	2023			2022
REVENUE	$	2,377,205		$	3,028,945

COST OF REVENUE		(2,008,308	)		(2,672,612	)

GROSS PROFIT		368,897			356,333

OTHER INCOME		117,344			46,394

OPERATING EXPENSES
General and administrative		(536,872	)		(368,036	)

(LOSS)/PROFIT FROM OPERATIONS		(50,631	)		34,691

FINANCE COSTS		(2,445	)		(3,326	)

(LOSS)/PROFIT BEFORE TAX		(53,076	)		31,365

Tax expense		(15,990	)		(14,299	)

NET (LOSS)/PROFIT	$	(69,066	)	$	17,066

Other comprehensive income:
Foreign currency translation loss		(39,039	)		(68,776	)
COMPREHENSIVE LOSS	$	(108,105	)	$	(51,710	)

Earnings per share - Basic and diluted		(0.001	)		0.000
Weighted average number of common shares outstanding – Basic and diluted		173,718,152			171,218,152

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

BIONEXUS GENE LAB CORP

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

AS OF MARCH 31, 2023 AND 2022

(Amount expressed in United States Dollars (“US$))

										Accumulated
					Additional					other
	Common stock				paid in			Accumulated		comprehensive			Total
	Number of shares		Amount		capital			surplus		loss			Equity
Balance as of December 31, 2021		171,218,152	$	10,779,574	$	(5,011,891	)	$	1,512,358	$	(100,262	)	$	7,179,779
Net profit for the period		-		-		-			17,066		-			17,066
Foreign currency translation loss		-		-		-			-		(68,776	)		(68,776	)
Balance as of March 31, 2022		171,218,152	$	10,779,574	$	(5,011,891	)	$	1,529,424	$	(169,038	)	$	7,128,069

											Accumulated
					Additional						other
	Common stock				paid in			Accumulated			comprehensive			Total
	Number of shares		Amount		capital			surplus			loss			Equity
Balance as of December 31, 2022		173,718,152	$	10,779,574	$	(5,011,891	)	$	1,156,392		$	(409,062	)	$	6,665,013
Net loss for the period		-		-		-			(69,066	)		-			(69,066	)
Foreign currency translation loss		-		-		-			-			(39,039	)		(39,039	)
Balance as of March 31, 2023		173,718,152	$	10,779,574	$	(5,011,891	)	$	1,087,326		$	(448,101	)	$	6,556,908

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

	Three months ended March 31,
	2023			2022
Cash flows from operating activities:
Net (loss)/profit	$	(69,066	)	$	17,066

Adjustments to reconcile net (loss)/profit to net cash (used in)/generated from operating activities:
Amortization of right of use asset		3,972			4,341
Depreciation of property, plant and equipment		20,897			22,307
Dividend income		(8,692	)		(7,230	)
Fair value loss/(gain) on other investments		(37,399	)		3,779
Gain on disposal of other investments		(4	)		-
Operating (loss)/profit before working capital changes		(90,292	)		40,263

Changes in operating assets and liabilities:
Inventories		78,171			(126,988	)
Trade and other receivables		335,512			330,316
Deferred cost of revenue		-			67,606
Trade and other payables		(433,061	)		(208,629	)
Advance payment from customer		(7,801	)		(30,200	)
Deferred revenue		-			(77,276	)
Operating lease liabilities		(4,366	)		(5,007	)
Tax recoverable		3,540			(27,924	)
Net cash used in operating activities		(118,297	)		(37,839	)

Cash flows from investing activities:
Acquisition of other investment		(13,646	)		(172,172	)
Dividend income		8,692			7,230
Purchase of plant and equipment		(102	)		(32,191	)
Net cash used in investing activities		(5,056	)		(197,133	)

Foreign currency translation adjustment		(22,299	)		(44,625	)
NET CHANGE IN CASH AND CASH EQUIVALENTS		(145,652	)		(279,597	)
CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL YEAR		2,118,864			2,123,919

CASH AND CASH EQUIVALENTS, END OF FINANCIAL YEAR	$	1,973,212		$	1,844,322

CASH AND CASH EQUIVALENTS INFORMATION:
Fixed deposits placed with financial institutions	$	1,566,425		$	1,237,472
Cash at bank		406,787			606,850
Cash and cash equivalents, end of financial year		1,973,212			1,844,322

Supplementary cash flow information:
Interest paid	$	(2,445	)	$	(3,326	)
Income taxes paid		(12,438	)		(41,946	)

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND

BioNexus Gene Lab Corp. (the “Company”) was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, the Company acquired all the outstanding capital stock of BGS Lab Sdn. Bhd., a Malaysian corporation (“BioNexus Malaysia”). BioNexus Malaysia was incorporated in Malaysia on April 7, 2015 which it then subsequently changed its name to Bionexus Gene Lab Sdn. Bhd.

The principal office address is Unit 02 Level 10, Tower B, Vertical Business Suite, No. 8 Jalan Kerinchi, Bangsar South, 59200 Kuala Lumpur, Malaysia, our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. We also have a blood collection center located at 1st floor, Lifecare Medical Centre, Kuala Lumpur, Malaysia.

On December 31, 2020, the Company consummated its acquisition of Chemrex Corporation Sdn. Bhd. (“Chemrex”), pursuant to a Share Exchange Agreement by and among the Company, Chemrex and the Chemrex shareholders wherein the Company acquired all the issued and outstanding shares of capital stock of Chemrex from the Chemrex shareholders in exchange for 68,487,261 shares of common stock of the Company.

The acquisition of Chemrex has been accounted for as a common control transaction as there is no change in the control over the assets acquired and liabilities assumed. The net assets are derecognized by the transferring entity (i.e. Chemrex) and recognized by the receiving entity (i.e. the Company). The difference between the consideration transferred and the carrying amounts of the net assets is recognized in equity.

The financial statements of the receiving entity report the results of operations for the period in which the transfer occurs as though the transfer of net assets or exchange of equity interests had occurred at the beginning of the period. Results of operations for that period will thus comprise those of the previously separate entities combined from the beginning of the period to the date the transfer is completed and those of the combined operations from that date to the end of the period. The comparative financial statements were not adjusted retrospectively as Chemrex was not under common control during the comparative period.

The corporate structure as at March 31, 2023 is depicted below:

		BioNexus Gene Lab Corp. (a Wyoming company)





	100%			100%

Bionexus Gene Lab Sdn Bhd (a Malaysia company)			Chemrex Corporation Sdn Bhd (a Malaysia Company)

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.

·	Basis of presentation

The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

·	Basis of consolidation

The condensed consolidated financial statements include the accounts of Bionexus Gene Lab Corp. and its subsidiaries. All significant inter-company balances and transactions within the Company have been eliminated upon consolidation.

·	Use of estimates

In preparing these condensed consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the periods reported. Actual results may differ from these estimates.

·	Cash and cash equivalents

Cash and cash equivalents represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of Three months or less as of the purchase date of such investments.

·	Trade receivables

Trade receivables are recorded at the invoiced amount and do not bear interest. Management reviews the adequacy of the allowance for impairment on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to adjust in the allowance when it is considered necessary. Trade balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

·	Inventories

Inventories consisting of products available for sell, are stated at the lower of cost or market value. Cost of inventory is determined using the first-in, first-out (FIFO) method. Inventory reserve is recorded to write down the cost of inventory to the estimated market value due to slow-moving merchandise and damaged goods, which is dependent upon factors such as historical and forecasted consumer demand, and promotional environment. The Company takes ownership, risks and rewards of the products purchased. Write downs are recorded in cost of revenues in the Statement of Operations and Comprehensive Income.

Leases

Prior to January 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases. Effective January 1, 2019, the Company adopted the guidance of ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The Company adopted ASC 842 using a modified retrospective approach. As a result, the comparative financial information has not been updated and the required disclosures prior to the date of adoption have not been updated and continue to be reported under the accounting standards in effect for those periods.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

·	Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on the straight-line basis to write off the cost over the following expected useful lives of the assets concerned.

The principal annual rates used are as follows:

Categories	Principal Annual Rates
Air conditioner		20	%
Buildings		2	%
Computer and software		33	%
Equipment		20	%
Furniture and fittings	10% to 20		%
Lab Equipment		10	%
Motor vehicle	10% to 20		%
Office equipment		20	%
Renovation	10% to 20		%
Signboard		10	%

Leasehold lands are depreciated over the period of lease term. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Freehold land is not depreciated. Property, plant and equipment under construction are not depreciated until the assets are ready for their intended use.

Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized. When properties are disposed, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

·	Impairment of long-lived assets

Long-lived assets primarily include goodwill, intangible assets and property, plant and equipment. In accordance with the provision of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, the Company generally conducts its annual impairment evaluation to its long-lived assets, usually in the fourth quarter of each fiscal year, or more frequently if indicators of impairment exist, such as a significant sustained change in the business climate. The recoverability of long-lived assets is measured at the lowest level group. If the total of the expected undiscounted future net cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. There has been no impairment charge for the years presented.

·	Revenue recognition

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

·	identify the contract with a customer;
·	identify the performance obligations in the contract;
·	determine the transaction price;
·	allocate the transaction price to performance obligations in the contract; and
·	recognize revenue as the performance obligation is satisfied.

The Company records revenue at point in time which is recognized upon goods delivered or services rendered.

·	Shipping and handling fees

Shipping and handling fees, if billed to customers, are included in revenue. Shipping and handling fees associated with inbound and outbound freight are expensed as incurred and included in selling and distribution expenses.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

·	Comprehensive income

ASC Topic 220, “Comprehensive Income” establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying statements of stockholders’ equity consists of changes in unrealized gains and losses on foreign currency translation and cumulative net change in the fair value of available-for-sale investments held at the balance sheet date. This comprehensive income is not included in the computation of income tax expense or benefit.

·	Income taxes

Income taxes are determined in accordance with the provisions of ASC Topic 740, “Income Taxes” (“ASC Topic 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclosed in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.

The Company conducts major businesses in Malaysia and is subject to tax in their own jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

·	Net earnings or loss per share

The Company calculates net earnings or loss per share in accordance with ASC Topic 260 “Earnings per share”. Basic earnings or loss per share is computed by dividing the net earnings or loss by the weighted average number of common shares outstanding during the period. Diluted earnings or loss per share is computed similar to basic earnings or loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

·	Foreign currencies translation

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations.

The functional currency of the Company is the United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. In addition, the subsidiaries maintain its books and record in a local currency, Malaysian Ringgit (“MYR” or “RM”), which is functional currency as being the primary currency of the economic environment in which the subsidiaries operate.

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income.

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year:

	March 31,		December 31,
	2023		2022
Period ended March 31, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate		4.4170		4.3900

	January 1, 2023 to March 31, 2023		January 1, 2022 to March 31, 2022
3 months average US$1: MYR exchange rate		4.3968		4.1938

·	Related parties

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

·	Fair value of financial instruments

The carrying value of the Company’s financial instruments: cash and cash equivalents, trade receivable, deposits and other receivables, amount due to related parties and other payables approximate at their fair values because of the short-term nature of these financial instruments.

The Company also follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a six-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

·	Level 1: Observable inputs such as quoted prices in active markets;

·	Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

·	Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions

As of March 31, 2023, and December 31, 2022, the Company did not have any nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements, at least annually, on a recurring basis, nor did the Company have any assets or liabilities measured at fair value on a non-recurring basis.

·	Recent accounting pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. The amendments in this Update address those stakeholders’ concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its consolidated financial statements.

FASB issues various Accounting Standards Updates relating to the treatment and recording of certain accounting transactions. On June 10, 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2014-10, Development Stage Entities (Topic 915) Elimination of Certain Financial Reporting Requirements, including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, which eliminates the concept of a development stage entity (DSE) entirely from current accounting guidance. The Company has elected adoption of this standard, which eliminates the designation of DSEs and the requirement to disclose results of operations and cash flows since inception.

NOTE 3 - TRADE RECEIVABLES

The Company has performed an analysis on all its trade receivables and determined that all amounts are collectible by the Company. As such, trade receivables are reflected as a current asset and no allowance for impairment has been recorded as of March 31, 2023 and December, 31, 2022. The Company’s trade receivables consist of receivable from customers which are unrelated to the Company. The account receivables are interest bearing at a rate of 6% per annum on a case to case basis for customers that exceeded credit term. The normal trade credit term is generally on 30 days to 90 days term.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 4 - INCOME TAXES

The Company provides for income taxes under ASC 740, “Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statements and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. It also requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

Provision for income taxes consisted of the following:

United States of America

The Company is registered in the State of Wyoming and is subject to the tax laws of the United States of America.

Malaysia

BioNexus Malaysia and Chemrex are both subject to Malaysia Corporate Tax, which is charged at the statutory income tax rate range is 24% on its assessable income. Under the amendment of Income Tax Act 1967 by the Finance Act 2020 and with effect from year of assessment 2020, companies with paid-up capital of RM2.5 million or less, and with annual business income of not more than RM50 million are subject to Small and Medium Enterprise Corporate Tax at 17% on chargeable income up to RM600,000 (2021: RM600,000) except for companies with investment holding nature or companies does not have gross income from business sources are subject to corporate tax at 24% on chargeable income.

	As of
	March 31,			December 31,
	2023			2022
Tax Recoverable
Local	$	-		$	-
Foreign, representing Malaysia		(27,823	)		(31,551	)
Tax Recoverable		(27,823	)		(31,551	)

Income tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		-			-
Income tax payables		-			-

Deferred tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		30,678			30,866
Deferred tax liabilities		30,678			30,866
Total		2,855			(685	)

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 5 – OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

Lease liabilities are measured at present value of the sum of remaining rental payment as of recognition with discount rate of 6.40% per annum adopted from Malayan Banking (Maybank) Berhad's base rate as a reference for discount rate, as this bank is the largest bank and national bank of Malaysia.

A single lease cost is recognized over the lease term on a generally straight-line basis. All cash payments of operating lease cost are classified within operating activities in the statement of cash flows.

Operating lease right of use assets as follows:	As of
	March 31,			December 31,
	2023			2022
Balance as of beginning of the year	$	55,730		$	41,090
Add: Addition of lease liabilities		-			32,281
Less: Amortization		(3,954	)		(15,534	)
Foreign translation differences		(341	)		(2,106	)
Balance	$	51,436		$	55,730

Operating lease liabilities as follows:
	March 31,			December 31,
	2023			2022
Balance as of beginning of the year	$	56,775		$	42,909
Add: Addition of lease liabilities		-			30,770
Less: gross repayment		(4,875	)		(19,618	)
Add: imputed interest		855			4,913
Foreign translation differences		(346	)		(2,199	)
Balance as of end of the year		52,409			56,775
Less: lease liability current portion		(16,733	)		(16,569	)
Lease liability non-current portion	$	35,676		$	40,206

The amortization of the right of use asset for the three months’ period ended March 31, 2023 and the three months’ period ended March 31, 2022 were $3,972 and $4,341 respectively.

Other information:	As of
	March 31, 2023			December 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating lease	$	(4,366	)	$	(126,686	)
Right of use assets obtained in exchange for operating lease liabilities		51,436			55,730
Remaining lease term for operating lease (years)		3.75			4
Weighted average discount rate for operating lease	$	6.40	%	$	6.40	%

Lease expenses for the three months’ period ended March 31, 2023 and the year ended December 31, 2022 were $855 and $4,913, respectively.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 6 - PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

	As of
	March 31,			December 31,
	2023			2022
Air conditioner	$	1,124		$	1,124
Computer and software		2,516			2,516
Equipment		60,525			60,525
Furniture and fittings		87,122			87,122
Lab equipment		320,102			320,102
Land and buildings		1,506,969			1,506,969
Motor vehicle		137,914			137,914
Office equipment		38,213			38,213
Renovation		107,414			107,414
Signboard		806			704
		2,262,705			2,262,603
(Less): Accumulated depreciation		(611,214	)		(590,317	)
Add: Foreign translation differences		(169,724	)		(133,982	)
Property, plant and equipment, net	$	1,481,767		$	1,511,708

Depreciation expense for the three months’ period ended March 31, 2023 and 2022 were $20,897 and $22,307 respectively.

NOTE 7 - OTHER INVESTMENTS

	As of
	March 31,			December 31,
	2023			2022
As of beginning of the year	$	1,150,898		$	749,027
Addition during the year		13,646			511,706
Disposal during the year		-			(1,776	)
Fair value loss		37,399			(70,628	)
Foreign exchange translation		(7,268	)		(37,431	)
As of end of the year	$	1,194,675		$	1,150,898

The other investments consist of the following shares:

	As of
	March 31,		December 31,
	2023		2022
Investment in quoted shares:
Malaysia		689,531		659,970
Singapore		94,757		101,426
Hong Kong		410,387		389,502
	$	1,194,675	$	1,150,898

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 8 - TRADE PAYABLES

Trade payables are amounts billed to the Company by suppliers for goods and services in the ordinary course of business. All amounts have short-term repayment terms and vary by supplier.

NOTE 9 - CONCENTRATION OF RISKS

a) Major customers

During the period, the Company did not have any material recognizable major customers accounted for 10% or more of the Company’s revenue for the financial period ended March 31, 2023 and 2022.

b) Major suppliers

For month ended March 31, 2023 and 2022, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at year ended are presented as follows:

	2023		2022		2023			2022			2023		2022
	Purchase				Percentage of purchases							Accounts payable trade
Vendor A	$	410,208	$	504,906		20.43	%		18.89	%	$	408,334	$	502,559
Vendor B	$	314,739	$	333,751		15.67	%		12.49	%	$	313,300	$	332,200
Vendor C	$	213,965	$	449,494		10.65	%		16.82	%	$	199,312	$	178,749
	$	938,912	$	1,288,151		46.75	%		48.20	%	$	920,946	$	1,013,508

NOTE 10 - STOCK HOLDERS’ EQUITY

As at March 31, 2023 and 2022, the Company issued and outstanding common stock is 173,718,152 and 171,218,152 shares respectively.

NOTE 11 - SEGMENTED INFORMATION

At March 31, 2023, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

		BioNexus Gene Lab Corp. (a Wyoming company)





	100%			100%

Bionexus Gene Lab Sdn Bhd (a Malaysia company)			Chemrex Corporation Sdn Bhd (a Malaysia Company)

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

For the quarter ended March 31, 2023, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

	BioNexus Malaysia			Chemrex			BGLC			Total
	Three months ended March 31, 2023

REVENUE	$	7,436		$	2,369,769		$	-		$	2,377,205

COST OF REVENUE		(5,347	)		(2,002,961	)		-			(2,008,308	)

GROSS /PROFIT		2,089			366,808			-			368,897

OTHER INCOME		1,126			116,218			-			117,344

OPERATING EXPENSES
General and administrative		(46,255	)		(383,177	)		(107,440	)		(536,872	)

(LOSS)/PROFIT FROM OPERATIONS		(43,040	)		99,849			(107,440	)		(50,631	)

FINANCE COSTS		(666	)		(1,779	)		-			(2,445	)

(LOSS)/PROFIT BEFORE TAX		(43,706	)		98,070			(107,440	)		(53,076	)

Tax expense		-			(15,990	)		-			(15,990	)

NET (LOSS)/PROFIT	$	(43,706	)	$	82,080		$	(107,440	)	$	(69,066	)

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

	BioNexus Malaysia			Chemrex			BGLC			Total
	Three months ended March 31, 2022
REVENUE	$	24,269		$	3,004,676		$	-		$	3,028,945

COST OF REVENUE		(8,038	)		(2,664,574	)		-			(2,672,612	)

GROSS PROFIT		16,231			340,102			-			356,333

OTHER INCOME		2,076			44,306			12			46,394

OPERATING EXPENSES
General and administrative		(44,042	)		(297,769	)		(26,225	)		(368,036	)

(LOSS)/PROFIT FROM OPERATIONS		(25,735	)		86,639			(26,213	)		34,691

FINANCE COSTS		(799	)		(2,527	)		-			(3,326	)

PROFIT/(LOSS) BEFORE TAX		(52,269	)		170,751			(52,426	)		31,365

Tax expense		-			(14,299	)		-			(14,299	)

NET PROFIT/(LOSS)	$	(52,269	)	$	502,730		$	(52,426	)	$	17,066

	As of March 31, 2023 and December 31, 2022
	Total Assets				Total Liabilities
	2023		2022		2023		2022

BGLC & Bionexus	$	509,574	$	677,477	$	93,034	$	108,390
Chemrex		7,677,067		8,062,685		1,536,699		1,966,759
TOTAL		8,186,641		8,740,162		1,629,733		2,075,149

NOTE 12 - SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred after March 31, 2023 up through May 7, 2023 of these consolidated financial statements.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Description of Business

As used herein, unless the context otherwise indicates, references to the “Company,” “we,” “our,” “us,” “BioNexus” refer to BioNexus Gene Lab Corp., a Wyoming company (“BGLC”), and its wholly owned subsidiaries, Bionexus Gene Lab Sdn. Bhd. (“Bionexus Malaysia”), and Chemrex Corporation Sdn. Bhd. (“Chemrex”), both are Malaysian companies.

BGLC is an emerging molecular lab focused on the application of functional genomics to enable early detection of infectious diseases and cancers. On August 23, 2017, we acquired all of the outstanding capital stock of BioNexus Malaysia, which was incorporated in Malaysia on April 7, 2015. BioNexus Malaysia owns algorithm software, technology and know-how related to the detection of common diseases through blood analysis which we use in our business. Our non-invasive blood screening tests analyze changes in ribonucleic acid (or RNA) to Coronavirus, Dengue, HIV, HPV and the risk potentiality of cancers diseases. This unique blood genomic biomarker approach is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body currently.

The corporate and principal office address of the Company and BioNexus Malaysia is Unit 02, Level 10, Tower B, Avenue 3, The Vertical Business Suite II, Bangsar South, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia., our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. Another lab focuses on Covid-19 and Colon cancer screening is located at 4^th floor, Lifecare Diagnostic Centre, Kuala Lumpur, Malaysia. Our telephone number is (+60) 1221-26512 and our website is www.bionexusgenelab.com.

Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asean region. On December 31, 2020, we acquired all of the outstanding capital stock of Chemrex, which was incorporated in Malaysia on September 29, 2004.

Chemrex’s corporate office and distribution and storage center is located at 4 Jalan CJ 1/6 Kawasan Perusahaan Cheras Jaya, Selangor, Malaysia. Its phone number is (+60) 1922-23815 and website is www.chemrex.com.my.

Table of Contents

The results of operations of our subsidiary, BioNexus-Malaysia, with respect to its RNA screening process have been adversely impacted by the onset of the Covid-19 pandemic followed by a number of prominent variants, including Alpha, Beta, Delta, and Omicron. Although new variants are an expected part of the evolution of viruses, new variant is more aggressive, highly transmissible, vaccine-resistant, able to cause more severe disease in Malaysia. We believe that most people were reluctant to visit hospitals and clinics in view of the post Covid-19 Omicron and its subvariants for fear of transmission from other patients or medical staff. Since our RNA screening is administered at a diagnostic center, our business has been adversely affected as a result.

The results of operations for Chemrex were adversely impacted during fiscal year 2022 and the 1^st quarter of 2023 as businesses of Chemrex customers especially the manufacturers had suffered significant impact. Many of them across the country saw their supply chains interrupted, demand for their products and services decline, shortages in supplies and inputs.

Recent Developments.

We had proposed an annual $28m screening project to the Chief Secretary of the Health Ministry of Malaysia for a nationwide RNA screening on 0.2% of the population aged 40 and above. The Deputy Director General from Public Health met us on January 17, 2023 to examine the cost effectiveness of our RNA screening. While the Federal government is studying our proposal, Sabah state government planned to allocate $2.5m to establish a lab in Kota Kinabalu, Sabah capital city for Bionexus-Malaysia to work with local hospitals and state insurance corporation. Meanwhile, we had presented our technology and expansion plan nationally and globally to the Minister of Science and Technology. We received favorable response and we are advised to submit for a $2m technology grant for the continuation of research, commercialization and expansion.

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year:

	March 31,		December 31,
	2023		2022
Period ended March 31, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate		4.4170		4.3900

	January 1, 2023 to March 31, 2023		January 1, 2022 to March 31, 2022
3 months average US$1: MYR exchange rate		4.3968		4,1938

Table of Contents

Results of Operations

Three Months Ended March 31, 2023 Compared with the Three Months Ended March 31, 2022.

The following table sets forth key selected financial data for the three months ended March 31, 2023 and 2022.

Consolidated

	Three months ended
	March 31,
	2023			2022
REVENUE	$	2,377,205		$	3,028,945

COST OF REVENUE		(2,008,308	)		(2,672,612	)

GROSS PROFIT		368,897			356,333

OTHER INCOME		117,344			46,394

OPERATING EXPENSES
General and administrative		(536,872	)		(368,036	)

(LOSS)/PROFIT FROM OPERATIONS		(50,631	)		34,691

FINANCE COSTS		(2,445	)		(3,326	)

(LOSS)/PROFIT BEFORE TAX		(53,076	)		31,365

Tax expense		(15,990	)		(14,299	)

NET (LOSS)/PROFIT	$	(69,066	)	$	17,066
Other comprehensive income:
Foreign currency loss		(39,039	)		(68,776	)

COMPREHENSIVE LOSS	$	(108,105	)	$	(51,710	)

Table of Contents

Segmented Information

	BioNexus Malaysia			Chemrex			BioNexus Malaysia			Chemrex
	Three months ended March 31, 2023						Three months ended March 31, 2022
REVENUE	$	7,436		$	2,369,769		$	24,269		$	3,004,676

COST OF REVENUE		(5,347	)		(2,002,961	)		(8,038	)		(2,664,574	)

GROSS PROFIT		2,089			366,808			16,231			340,102

OTHER INCOME		1,126			116,218			2,076			44,306

OPERATING EXPENSES
General and administrative		(46,255	)		(383,177	)		(44,042	)		(297,769	)

FINANCE COSTS		(666	)		(1,779	)		(799	)		(2,527	)

(LOSS)/PROFIT BEFORE TAX		(43,706	)		98,070			(52,269	)		170,751

Tax expense		-			(15,990	)		-			(14,299	)

NET (LOSS)/PROFIT	$	(43,706	)	$	82,080		$	(52,269	)	$	156,452

Revenue. For the quarter ended March 31, 2023, we had total revenue of $2,377,205 as compared to total revenue of $3,028,945 for the quarter ended March 31, 2022, decreased by 21.5% from the prior quarter.

Chemrex contributed $2,369,769 (99.7%) of the total revenue for the current quarter ended March 31, 2023 as compared to $3,004,676 (99.2%) of the total revenue for the quarter ended March 31, 2022. Chemrex’s revenues had a decrease by $634,907 of 21.13% from prior quarter. The revenue decreased in first quarter of 2023 was due to material cost for Resin & Fiberglass mat has been reduced in Malaysia. As a result, we adjusted the selling price of our product to stay competitive. Chemrex is catching up with the markets change post pandemic by targeting the right manufacturers to reduce cost of logistics and warehousing meanwhile may scarify some small retail business.

BioNexus-Malaysia contributed $7,436 (0.3%) of the total revenue for the quarter ended March 31, 2023 as compared to revenue of $24,269 (0.8%) of the total revenue from the quarter ended March 31, 2022. Revenues had decreased by $16,833 from prior quarter of $24,269, a 69.4% decrease. RNA screening process have been adversely impacted by the onset of the Covid-19 pandemic followed by a number of prominent variants, including Alpha, Beta, Delta, and Omicron. Although new variants are an expected part of the evolution of viruses, new variant is more aggressive, highly transmissible, vaccine-resistant, able to cause more severe disease in Malaysia. We believe that most people were reluctant to visit hospitals and clinics in view of the post Covid-19 Omicron and its subvariants for fear of transmission from other patients or medical staff. Since our RNA screening is administered at a diagnostic center, our business had been adversely affected as a result.

Cost of Revenue. For the quarter ended March 31, 2023, we incurred $2,008,308 in cost of revenues, as compared to $2,672,612 for the quarter ended March 31, 2022, a decrease of approximately 24.9% was due to reason as stated above.

Chemrex had incurred $2,002,961 (99.7%) of the total cost of revenue during the current quarter period ended March 31, 2023 as compared to the quarter ended March 31, 2022 wherein Chemrex had incurred $2,664,574 (99.7%) of the total cost of revenue. The decrease in Chemrex’s cost of revenues of 24.8% for the current period was due to its decreased revenues and reason as stated above.

BioNexus had incurred $5,347 (0.3%) of the total cost of revenues during the current quarter period ended March 31, 2023 as compared to $8,038 (0.3%) for the quarterly period ended March 31, 2022. Cost of revenue had decreased by $2,691 from prior quarter of 33.5% decrease was due to its decreased revenues and reason as stated above.

Table of Contents

Gross Profit. For the quarterly period ended March 31, 2023, we had total gross profit of $368,897 as compared to gross profit of $356,333 for the quarterly period ended March 31, 2022, an increase by approximately 3.5% from the prior period.

Chemrex contributed $366,808 (99.4%) of the total gross profit for the current quarter ended March 31, 2023 as compared to $340,106 (95.4%) of the total gross profit for the quarter ended March 31, 2022. Chemrex’s gross profit increased by $26,706 from prior quarter, approximately 7.85% increase. The gross profit increase for Chemrex in current quarter was due to cost of revenue had been reduced.

BioNexus-Malaysia contributed $2,089 (0.6%) of the total gross profit of $368,897 for the current quarter ended March 31, 2023 as compared to gross profit of $16,231 (4.6%) of the total gross profit from the quarter ended March 31, 2022. The substantial decrease by approximately 87.1% from the prior period due to its decreased revenues and less lab consumables purchased for the same reason stated above.

Other Income. For the quarterly period ended March 31, 2023, we had of $117,344, as compared to of $46,394 for the quarterly period ended March 31, 2022, an increase of approximately 152.9%.

Chemrex contributed $116,218 (99%) of other income for the current quarter ended March 31, 2023 as compared to $44,306 (95.5%) of the other income for the quarter ended March 31, 2022. Chemrex’s other income increased by 162.3% due to gain on fair value of investment, bank interest earning and unrealized forex gain.

BioNexus-Malaysia contributed $1,126 (1%) of other income for the current quarter ended March 31, 2023 as compared to $2,076 (4.5%) of the other income for the quarter ended March 31, 2022. The decrease of 45.8% due to bank interest earning has been reduced.

Operating Expenses. For the quarter ended March 31, 2023, we had total operating expense of $536,872 as compared to total operating expenses of $368,036 for the quarter ended March 31, 2022, an increase by approximately 45.9%. It was due to general and administrative expenses which includes depreciation of fixed assets, employee compensation and benefits, professional fees and marketing and travel expenses.

Chemrex had incurred $383,177 (71.4%) of the total operating expenses for the current quarter ended March 31, 2023 as compared to $297,769 (80.9%) of the total operating expenses for the quarter ended March 31, 2022, an increase by 28.68%. The increase in operating expenses was due to commission, travelling and increased in medical expenses.

BioNexus-Malaysia had incurred $46,255 (8.6%) of the total operating expenses for the current quarter ended March 31, 2023 as compared to $44,042 (12%) of the total operating expenses for the quarter ended March 31, 2022, a slightly increase by 5%. The increase in operating costs of the current quarter was due to travelling and cost incurred for vehicle maintenance.

BGLC, the holding company had incurred $107,440 (20%) of total operating expenses for the current quarter ended March 31, 2023 as compared to $26,255 (7.1%) of the total operating expenses for the quarter ended March 31, 2022. The increase of $81,215, approximately 309.69% in operating costs for the quarter ended March 31, 2023 was due to the expenses on filing fees for form S-1, consultant fees for capital & corporation advisory services, fees for three independent board members and audit committee, SEC compliance services, SEC registration fee, increased fee of shareholder maintenance by Securities Transfer Corporation and an additional review fee for S-1.

Loss/Profit from Operations. We had a loss from operations of $50,631 for the quarter ended March 31, 2023 as compared to a profit of $34,691 for the quarter ended March 31, 2022, an increase by approximately 145.9% from the prior period, for the reasons discussed above.

Income tax expense. For the quarter ended March 31, 2023, we had estimated income tax expenses of $15,990 as compared to $14,299 for the quarter ended March 31, 2022 for Chemrex. There was no tax provision for Bio-Nexus Malaysia for the quarters ended March 31, 2023 and 2022.

Foreign currency exchange loss. We are exposed to fluctuations in foreign exchange rates on the revaluation of monetary assets and liabilities denominated in currencies other than the US Dollar. Therefore, any change in the relevant exchange rate would require us to recognize a transaction gain or loss on revaluation. For the three-month period ended March 31, 2023, we experienced a foreign currency loss of $39,039 as compared with a foreign currency loss of $68,776 for the three-month period ended March 31, 2022.

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

As of March 31, 2023, we had working capital of $3,895,384 compared with working capital of $4,017,749 as of December 31, 2022. The decrease in working capital as of March 31, 2023 from December 31, 2022 was due principally to the decrease in cash used in our operations.

Our primary uses of cash had been for operations. The main sources of cash was generated from operational revenues and the private placement of our common stock. The following trends could result in a material decrease in our liquidity over the near to long term:

	·	Addition of administrative and marketing personnel as the business grows,
	·	Development of a Company website,
	·	Increases in advertising and marketing in order to attempt to generate more revenues, and
	·	The cost of being a public company.

The Company believes that cash flow from operations together will be sufficient to sustain its current level of operations for at least the next 12 months of operations.

The following is a summary of the Company’s cash flows provided by (used in) / generated from operating, investing, and financing activities for the three months ended March 31, 2023 and 2022:

	Three months ended
	March 31,
	2023			2022
Net cash used in Operating Activities	$	(118,297	)	$	(37,839	)
Net cash used in investing activities		(5,056	)		(197,133	)
Net cash generated from/(used in) financing activities		-			-
Foreign currency translation adjustment		(22,299	)		(44,625	)
Net Change in Cash and Cash Equivalents	$	(145,652	)	$	(279,597	)

Operating Activities

During the first quarter ended March 31, 2023, the Company incurred a net loss of $69,066 which, after adjusting for amortization, depreciation, dividend income, fair value gain on share investment, a decrease in inventories, trade receivables and a substantial reduction in trade payables, operating lease liabilities, advance payment from customer, resulted in net cash of $118,297 being used in activities during the first quarter ended 2023. By comparison, during the first quarter ended March 31, 2022, the Company had a net profit of $17,066 after adjusting for amortization, depreciation, dividend income, fair value loss on share investments, an increase in inventories and a decrease in trade receivables, deposits, deferred cost of revenue, a substantial reduction in trade payables, operating lease liabilities, advance payment from customer, deferred revenue, resulted in net cash of $37,839 being used in operating activities during the period.

Investing Activities

During the first quarter ended March 31, 2023, the Company had net cash of $5,056 used in investment activities from acquisition of share investment of $13,646 and purchase of plant & equipment of $102. During the first quarter ended March 31, 2022, the Company had net cash from acquisition of share investment of $172,172 and purchase of plant and equipment of $32,191 resulting in net cash used in financing activities of $197,133.

Financing Activities

During the first quarter ended March 31, 2023 and 2022, Company had no financing activities.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

Table of Contents

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this quarterly report, an evaluation was carried out by the Company’s management, with the participation of the principal executive officer and the principal financial officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act (“Exchange Act”) as of March 31, 2023. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

Based on that evaluation, the Company’s management concluded, as of the end of the period covered by this report, that the Company’s disclosure controls and procedures were capable in recording, processing, summarizing, and reporting information required to be disclosed, within the time periods specified in the Commission’s rules and forms, and that such information was accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

Management’s Report on Internal Control over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process, under the supervision of the principal executive officer and the principal financial officer, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with United States generally accepted accounting principles (GAAP). Internal control over financial reporting includes those policies and procedures that:

Pertain to the maintenance of records that is in reasonable detail accurately and fairly reflect the transactions and dispositions of the Company’s assets;

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

The Company’s management had assessed the effectiveness of our internal control over financial reporting as of March 31, 2023, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, which assessment identified material weaknesses in internal control over financial reporting had improved. A material weakness could create reasonable possibility that a material misstatement in annual or interim financial statements. The management considers its internal control over financial reporting required further improvement.

Management had concluded an internal control over financial reporting and glad to note that a majority of our Board of Directors were made up of independent directors and the Audit Committee comprised of all independent directors since 2022, the adequacy in the monitoring of required internal controls and procedures were improving.

While these control deficiencies did not result in any audit adjustments to our 2022 or 2021 interim or annual financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties.

To the extent reasonably possible, given our limited resources, upon consummation of a merger with a private operating company, the Company had been relying on three or more individuals. We were expanding our current board of directors to include additional independents willing to perform directorial functions. Since the recited remedial actions and we would hire or engage additional personnel, this material weakness would be overcome in the near term. Until such remedial actions could be realized, we would continue to rely on the advice of outside professionals and consultants.

This quarterly report does not include an attestation report of our registered public accounting firm regarding our internal controls over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to Section 404(c) of the Sarbanes-Oxley Act that permit us to provide only management’s report in this annual report.

Changes in Internal Controls over Financial Reporting

During the period ended March 31, 2023, there had been no change in internal control over financial reporting that had materially affected or was reasonably likely to materially affect our internal control over financial reporting.

Table of Contents

PART II OTHER INFORMATION

Item 1. Legal Proceedings.

There are presently no pending legal proceedings to which the Company or any of its property is subject, or any material proceedings to which any director, officer or affiliate of the Company, any owner of record or beneficially of more than five percent of any class of voting securities is a party or has a material interest adverse to the Company, and no such proceedings are known to the Company to be threatened or contemplated against it.

Item 2. Unregistered Sale of Equity Securities.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable to our Company.

Item 5. Other Information.

None

Table of Contents

Item 6. Exhibits.

Exhibit		Description

31.1		Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

31.2		Certification of the Company’s Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1		Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+

32.2		Certification of the Company’s Principal Accounting Officer and Principal Financial pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+

101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).*

101.SCH		Inline XBRL Taxonomy Extension Schema Document.*

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.*

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.*

101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document.*

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.*

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

__________

+	In accordance with SEC Release 33-8238, Exhibit 32.1 and 32.2 are being furnished and not filed.

*	Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BIONEXUS GENE LAB CORPORATION

/s/ Sook Keng Yeoh
Sook Keng Yeoh
Chief Executive Officer and Director
(Principal Executive Officer)

/s/ Wei Li Leong
Wei Li Leong
Chief Financial Officer
(Principal Financial and Accounting Officer)

May 9, 2023

EX-31.1 2 bion_ex311.htm CERTIFICATION bion_ex311.htm

EXHIBIT 31.1

CERTIFICATION

I, Chief Executive Officer of Bionexus Gene Lab Corporation (the “Registrant”), certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q of the Registrant for the fiscal quarter ended March 31, 2023;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.

The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.

The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Dated: May 9, 2023

/s/ Sook Keng Yeoh

Sook Keng Yeoh

Chief Executive Officer and Director

(Principal Executive Officer)

EX-31.2 3 bion_ex312.htm CERTIFICATION bion_ex312.htm

EXHIBIT 31.2

CERTIFICATION

I, Chief Financial Officer of Bionexus Gene Lab Corporation (the “Registrant”), certify that:

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Dated: May 9, 2023

/s/ Wei Li Leong

Wei Li Leong

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-32.1 4 bion_ex321.htm CERTIFICATION bion_ex321.htm

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officers of the registrant certify, to the best of their knowledge, that the registrant’s Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the “Form 10-Q”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Form 10-Q, fairly presents, in all material respects, the financial condition and results of operations of the registrant.

Bionexus Gene Lab Corporation

Dated: May 9, 2023

/s/ Sook Keng Yeoh

Sook Keng Yeoh

Chief Executive Officer

(Principal Executive Officer)

EX-32.2 5 bion_ex322.htm CERTIFICATION bion_ex322.htm

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL ACCOUNTING OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Bionexus Gene Lab Corporation

Dated: May 9, 2023

/s/ Wei Li Leong

Wei Li Leong

Chief Financial Officer

(Principal Accounting Officer)

EX-101.SCH 6 bion-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - TRADE RECEIVABLES link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - PROPERTY PLANT AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - OTHER INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - TRADE PAYABLES link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - CONCENTRATION OF RISKS link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - SEGMENTED INFORMATION link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - OTHER INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - CONCENTRATION OF RISKS (Tables) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - SEGMENTED INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - TRADE RECEIVABLES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 3) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - OTHER INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000040 - Disclosure - OTHER INVESTMENTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000041 - Disclosure - CONCENTRATION OF RISKS (Details) link:presentationLink link:calculationLink link:definitionLink 000042 - Disclosure - CONCENTRATION OF RISKS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000043 - Disclosure - STOCK HOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000044 - Disclosure - SEGMENTED INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 000045 - Disclosure - SEGMENTED INFORMATION (Details 1) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 bion-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Ex Transition Period Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address Address Line 3 Entity Address City Or Town Entity Address Country Entity Address Postal Zip Code City Area Code Local Phone Number Entity Interactive Data Current CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS CURRENT ASSETS Cash and bank balances Fixed deposits placed with financial institutions Trade receivables Other receivables, deposits and prepayments Tax recoverable Inventories Total current assets [Assets, Current] NON-CURRENT ASSETS Operating lease right of use assets Property, plant and equipment, net Other investments Total non-current assets [Assets, Noncurrent] TOTAL ASSETS [Assets] LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Trade payables Other payables and accrued liabilities Current portion of operating lease liabilities Advance payment from customer Total current liabilities [Liabilities, Current] NON-CURRENT LIABILITIES Non-current portion of operating lease liabilities Deferred tax liabilities Total non-current liabilities [Liabilities, Noncurrent] TOTAL LIABILITIES [Liabilities] STOCKHOLDERS' EQUITY As at March 31, 2023, common stock, no par value; 300,000,000 shares authorized and 173,718,152 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2022, common stock, no par value; 300,000,000 shares authorized and 173,718,152 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. Additional paid in capital Accumulated surplus Accumulated other comprehensive losses TOTAL STOCKHOLDERS' EQUITY [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY [Liabilities and Equity] Common stock, par value per share Common stock, shares authorized Common stock, shares outstanding Preferred stock, par value per share Preferred stock, shares authorized Preferred stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) REVENUE COST OF REVENUE [Cost of Revenue] GROSS PROFIT [Gross Profit] OTHER INCOME OPERATING EXPENSES General and administrative [General and Administrative Expense] (LOSS)/PROFIT FROM OPERATIONS [Operating Income (Loss)] FINANCE COSTS [Interest Expense] (LOSS)/PROFIT BEFORE TAX [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Tax expense [Income Tax Expense (Benefit)] NET (LOSS)/PROFIT [Net Income (Loss) Attributable to Parent] Other comprehensive income: Foreign currency translation loss COMPREHENSIVE LOSS [Comprehensive Income (Loss), Net of Tax, Attributable to Parent] Earnings per share - Basic and diluted Weighted average number of common shares outstanding - Basic and diluted CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (Unaudited) Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Additional Paid In Capital Accumulated Surplus/(Loss) Accumulated Other Comprehensive Income/(Loss) Balance, shares [Shares, Issued] Balance, amount Net profit for the period Foreign currency translation loss [Foreign currency translation loss] Balance, shares Balance, amount CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Cash flows from operating activities: Net (loss)/profit Adjustments to reconcile net (loss)/profit to net cash (used in)/generated from operating activities: Amortization of right of use asset Depreciation of property, plant and equipment Dividend income [Dividend income] Fair value loss/(gain) on other investments [Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)] Gain on disposal of other investments [Gain (Loss) on Sale of Other Investments] Operating (loss)/profit before working capital changes [Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities] Changes in operating assets and liabilities: Inventories [Increase (Decrease) in Inventories] Trade and other receivables [Increase (Decrease) in Accounts and Other Receivables] Deferred cost of revenue Trade and other payables Advance payment from customer [Increase (Decrease) in Customer Advances] Deferred revenue Operating lease liabilities Tax recoverable [Increase (Decrease) in Income Taxes Receivable] Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] Cash flows from investing activities: Acquisition of other investment [Payments to Acquire Other Investments] Dividend income [Proceeds from Equity Method Investment, Distribution, Return of Capital] Purchase of plant and equipment [Payments to Acquire Property, Plant, and Equipment] Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] Foreign currency translation adjustment NET CHANGE IN CASH AND CASH EQUIVALENTS [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect] CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL YEAR [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] CASH AND CASH EQUIVALENTS, END OF FINANCIAL YEAR CASH AND CASH EQUIVALENTS INFORMATION: Fixed deposits placed with financial institutions [Fixed deposits placed with financial institutions] Cash at bank Cash and cash equivalents, end of financial year Supplementary cash flow information: Interest paid [Interest Paid, Excluding Capitalized Interest, Operating Activities] Income taxes paid ORGANIZATION AND BUSINESS BACKGROUND ORGANIZATION AND BUSINESS BACKGROUND Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] TRADE RECEIVABLES TRADE RECEIVABLES Accounts and Nontrade Receivable [Text Block] INCOME TAXES INCOME TAXES Income Tax Disclosure [Text Block] OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES Lessee, Operating Lease, Liability, Maturity [Table Text Block] PROPERTY PLANT AND EQUIPMENT PROPERTY, PLANT AND EQUIPMENT OTHER INVESTMENTS OTHER INVESTMENTS [OTHER INVESTMENTS] TRADE PAYABLES TRADE PAYABLES [TRADE PAYABLES] CONCENTRATION OF RISKS CONCENTRATION OF RISKS Concentration Risk Disclosure [Text Block] STOCKHOLDERS EQUITY STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] SEGMENTED INFORMATION SEGMENTED INFORMATION Segment Reporting Disclosure [Text Block] SUBSEQUENT EVENTS SUBSEQUENT EVENTS Subsequent Events [Text Block] Basis of presentation Basis of consolidation Use of estimates Cash and cash equivalents Trade receivables Receivable [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Leases EX-101.CAL 8 bion-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 bion-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 bion-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2023	May 09, 2023
Cover [Abstract]
Entity Registrant Name	BIONEXUS GENE LAB CORP.
Entity Central Index Key	0001737523
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		173,718,152
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	333-229399
Entity Incorporation State Country Code	WY
Entity Tax Identification Number	35-2604830
Entity Address Address Line 1	Unit 02, Level 10 Tower B, Avenue 3, The Vertical
Entity Address Address Line 2	Business Suite II Bangsar South
Entity Address Address Line 3	No. 8 Jalan Kerinchi
Entity Address City Or Town	Kuala Lumpur
Entity Address Country	MY
Entity Address Postal Zip Code	59200
City Area Code	60
Local Phone Number	1221-26512
Entity Interactive Data Current	Yes

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and bank balances	$ 406,787	$ 611,849
Fixed deposits placed with financial institutions	1,566,425	1,507,015
Trade receivables	2,528,746	2,868,364
Other receivables, deposits and prepayments	29,346	25,240
Tax recoverable	27,823	31,551
Inventories	899,636	977,807
Total current assets	5,458,763	6,021,826
NON-CURRENT ASSETS
Operating lease right of use assets	51,436	55,730
Property, plant and equipment, net	1,481,767	1,511,708
Other investments	1,194,675	1,150,898
Total non-current assets	2,727,878	2,718,336
TOTAL ASSETS	8,186,641	8,740,162
CURRENT LIABILITIES
Trade payables	1,493,774	1,861,015
Other payables and accrued liabilities	37,550	103,370
Current portion of operating lease liabilities	16,733	16,569
Advance payment from customer	15,322	23,123
Total current liabilities	1,563,379	2,004,077
NON-CURRENT LIABILITIES
Non-current portion of operating lease liabilities	35,676	40,206
Deferred tax liabilities	30,678	30,866
Total non-current liabilities	66,354	71,072
TOTAL LIABILITIES	1,629,733	2,075,149
STOCKHOLDERS' EQUITY
As at March 31, 2023, common stock, no par value; 300,000,000 shares authorized and 173,718,152 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2022, common stock, no par value; 300,000,000 shares authorized and 173,718,152 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding.	10,929,574	10,779,574
Additional paid in capital	(5,011,891)	(5,011,891)
Accumulated surplus	1,087,326	1,156,392
Accumulated other comprehensive losses	(448,101)	(409,062)
TOTAL STOCKHOLDERS' EQUITY	6,556,908	6,665,013
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 8,186,641	$ 8,740,162

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
CONDENSED CONSOLIDATED BALANCE SHEETS
Common stock, par value per share	$ 0	$ 0
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares outstanding	173,718,152	173,718,152
Preferred stock, par value per share	$ 0	$ 0
Preferred stock, shares authorized	30,000,000	30,000,000
Preferred stock, shares outstanding	0	0

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
REVENUE	$ 2,377,205	$ 3,028,945
COST OF REVENUE	(2,008,308)	(2,672,612)
GROSS PROFIT	368,897	356,333
OTHER INCOME	117,344	46,394
OPERATING EXPENSES
General and administrative	(536,872)	(368,036)
(LOSS)/PROFIT FROM OPERATIONS	(50,631)	34,691
FINANCE COSTS	(2,445)	(3,326)
(LOSS)/PROFIT BEFORE TAX	(53,076)	31,365
Tax expense	(15,990)	(14,299)
NET (LOSS)/PROFIT	(69,066)	17,066
Other comprehensive income:
Foreign currency translation loss	(39,039)	(68,776)
COMPREHENSIVE LOSS	$ (108,105)	$ (51,710)
Earnings per share - Basic and diluted	$ (0.001)	$ 0.000
Weighted average number of common shares outstanding - Basic and diluted	173,718,152	171,218,152

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (Unaudited) - USD ($)	Total	Common Stock	Additional Paid In Capital	Accumulated Surplus/(Loss)	Accumulated Other Comprehensive Income/(Loss)
Balance, shares at Dec. 31, 2021		171,218,152
Balance, amount at Dec. 31, 2021	$ 7,179,779	$ 10,779,574	$ (5,011,891)	$ 1,512,358	$ (100,262)
Net profit for the period	17,066	0	0	17,066	0
Foreign currency translation loss	(68,776)	$ 0	0	0	(68,776)
Balance, shares at Mar. 31, 2022		171,218,152
Balance, amount at Mar. 31, 2022	7,128,069	$ 10,779,574	(5,011,891)	1,529,424	(169,038)
Balance, shares at Dec. 31, 2022		173,718,152
Balance, amount at Dec. 31, 2022	6,665,013	$ 10,779,574	(5,011,891)	1,156,392	(409,062)
Net profit for the period	(69,066)	0	0	(69,066)	0
Foreign currency translation loss	(39,039)	$ 0	0	0	(39,039)
Balance, shares at Mar. 31, 2023		173,718,152
Balance, amount at Mar. 31, 2023	$ 6,556,908	$ 10,779,574	$ (5,011,891)	$ 1,087,326	$ (448,101)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net (loss)/profit	$ (69,066)	$ 17,066
Adjustments to reconcile net (loss)/profit to net cash (used in)/generated from operating activities:
Amortization of right of use asset	3,972	4,341
Depreciation of property, plant and equipment	20,897	22,307
Dividend income	(8,692)	(7,230)
Fair value loss/(gain) on other investments	(37,399)	3,779
Gain on disposal of other investments	(4)	0
Operating (loss)/profit before working capital changes	(90,292)	40,263
Changes in operating assets and liabilities:
Inventories	78,171	(126,988)
Trade and other receivables	335,512	330,316
Deferred cost of revenue	0	67,606
Trade and other payables	(433,061)	(208,629)
Advance payment from customer	(7,801)	(30,200)
Deferred revenue	0	(77,276)
Operating lease liabilities	(4,366)	(5,007)
Tax recoverable	3,540	(27,924)
Net cash used in operating activities	(118,297)	(37,839)
Cash flows from investing activities:
Acquisition of other investment	(13,646)	(172,172)
Dividend income	8,692	7,230
Purchase of plant and equipment	(102)	(32,191)
Net cash used in investing activities	(5,056)	(197,133)
Foreign currency translation adjustment	(22,299)	(44,625)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(145,652)	(279,597)
CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL YEAR	2,118,864	2,123,919
CASH AND CASH EQUIVALENTS, END OF FINANCIAL YEAR	1,973,212	1,844,322
CASH AND CASH EQUIVALENTS INFORMATION:
Fixed deposits placed with financial institutions	1,566,425	1,237,472
Cash at bank	406,787	606,850
Cash and cash equivalents, end of financial year	1,973,212	1,844,322
Supplementary cash flow information:
Interest paid	(2,445)	(3,326)
Income taxes paid	$ (12,438)	$ (41,946)

XML 17 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND BUSINESS BACKGROUND

3 Months Ended

Mar. 31, 2023

ORGANIZATION AND BUSINESS BACKGROUND

ORGANIZATION AND BUSINESS BACKGROUND

NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND

The corporate structure as at March 31, 2023 is depicted below:

		BioNexus Gene Lab Corp. (a Wyoming company)





	100%			100%

Bionexus Gene Lab Sdn Bhd (a Malaysia company)			Chemrex Corporation Sdn Bhd (a Malaysia Company)

XML 18 R8.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2023

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

·	Basis of presentation

The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

·	Basis of consolidation

·	Use of estimates

·	Cash and cash equivalents

·	Trade receivables

·	Inventories

Leases

·	Property, plant and equipment

The principal annual rates used are as follows:

Categories	Principal Annual Rates
Air conditioner		20	%
Buildings		2	%
Computer and software		33	%
Equipment		20	%
Furniture and fittings	10% to 20		%
Lab Equipment		10	%
Motor vehicle	10% to 20		%
Office equipment		20	%
Renovation	10% to 20		%
Signboard		10	%

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.

·	Impairment of long-lived assets

·	Revenue recognition

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

·	identify the contract with a customer;
·	identify the performance obligations in the contract;
·	determine the transaction price;
·	allocate the transaction price to performance obligations in the contract; and
·	recognize revenue as the performance obligation is satisfied.

The Company records revenue at point in time which is recognized upon goods delivered or services rendered.

·	Shipping and handling fees

·	Comprehensive income

·	Income taxes

·	Net earnings or loss per share

·	Foreign currencies translation

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year:

	March 31,		December 31,
	2023		2022
Period ended March 31, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate		4.4170		4.3900

	January 1, 2023 to March 31, 2023		January 1, 2022 to March 31, 2022
3 months average US$1: MYR exchange rate		4.3968		4.1938

·	Related parties

·	Fair value of financial instruments

·	Level 1: Observable inputs such as quoted prices in active markets;

·	Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

·	Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions

·	Recent accounting pronouncements

XML 19 R9.htm IDEA: XBRL DOCUMENT

TRADE RECEIVABLES

3 Months Ended

Mar. 31, 2023

TRADE RECEIVABLES

TRADE RECEIVABLES

NOTE 3 - TRADE RECEIVABLES

XML 20 R10.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

Mar. 31, 2023

INCOME TAXES

INCOME TAXES

NOTE 4 - INCOME TAXES

Provision for income taxes consisted of the following:

United States of America

The Company is registered in the State of Wyoming and is subject to the tax laws of the United States of America.

Malaysia

	As of
	March 31,			December 31,
	2023			2022
Tax Recoverable
Local	$	-		$	-
Foreign, representing Malaysia		(27,823	)		(31,551	)
Tax Recoverable		(27,823	)		(31,551	)

Income tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		-			-
Income tax payables		-			-

Deferred tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		30,678			30,866
Deferred tax liabilities		30,678			30,866
Total		2,855			(685	)

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

3 Months Ended

Mar. 31, 2023

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

NOTE 5 – OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

Operating lease right of use assets as follows:	As of
	March 31,			December 31,
	2023			2022
Balance as of beginning of the year	$	55,730		$	41,090
Add: Addition of lease liabilities		-			32,281
Less: Amortization		(3,954	)		(15,534	)
Foreign translation differences		(341	)		(2,106	)
Balance	$	51,436		$	55,730

Operating lease liabilities as follows:
	March 31,			December 31,
	2023			2022
Balance as of beginning of the year	$	56,775		$	42,909
Add: Addition of lease liabilities		-			30,770
Less: gross repayment		(4,875	)		(19,618	)
Add: imputed interest		855			4,913
Foreign translation differences		(346	)		(2,199	)
Balance as of end of the year		52,409			56,775
Less: lease liability current portion		(16,733	)		(16,569	)
Lease liability non-current portion	$	35,676		$	40,206

The amortization of the right of use asset for the three months’ period ended March 31, 2023 and the three months’ period ended March 31, 2022 were $3,972 and $4,341 respectively.

Other information:	As of
	March 31, 2023			December 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating lease	$	(4,366	)	$	(126,686	)
Right of use assets obtained in exchange for operating lease liabilities		51,436			55,730
Remaining lease term for operating lease (years)		3.75			4
Weighted average discount rate for operating lease	$	6.40	%	$	6.40	%

Lease expenses for the three months’ period ended March 31, 2023 and the year ended December 31, 2022 were $855 and $4,913, respectively.

XML 22 R12.htm IDEA: XBRL DOCUMENT

PROPERTY PLANT AND EQUIPMENT

3 Months Ended

Mar. 31, 2023

PROPERTY PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT

NOTE 6 - PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

	As of
	March 31,			December 31,
	2023			2022
Air conditioner	$	1,124		$	1,124
Computer and software		2,516			2,516
Equipment		60,525			60,525
Furniture and fittings		87,122			87,122
Lab equipment		320,102			320,102
Land and buildings		1,506,969			1,506,969
Motor vehicle		137,914			137,914
Office equipment		38,213			38,213
Renovation		107,414			107,414
Signboard		806			704
		2,262,705			2,262,603
(Less): Accumulated depreciation		(611,214	)		(590,317	)
Add: Foreign translation differences		(169,724	)		(133,982	)
Property, plant and equipment, net	$	1,481,767		$	1,511,708

Depreciation expense for the three months’ period ended March 31, 2023 and 2022 were $20,897 and $22,307 respectively.

XML 23 R13.htm IDEA: XBRL DOCUMENT

OTHER INVESTMENTS

3 Months Ended

Mar. 31, 2023

OTHER INVESTMENTS

OTHER INVESTMENTS

NOTE 7 - OTHER INVESTMENTS

	As of
	March 31,			December 31,
	2023			2022
As of beginning of the year	$	1,150,898		$	749,027
Addition during the year		13,646			511,706
Disposal during the year		-			(1,776	)
Fair value loss		37,399			(70,628	)
Foreign exchange translation		(7,268	)		(37,431	)
As of end of the year	$	1,194,675		$	1,150,898

The other investments consist of the following shares:

	As of
	March 31,		December 31,
	2023		2022
Investment in quoted shares:
Malaysia		689,531		659,970
Singapore		94,757		101,426
Hong Kong		410,387		389,502
	$	1,194,675	$	1,150,898

XML 24 R14.htm IDEA: XBRL DOCUMENT

TRADE PAYABLES

3 Months Ended

Mar. 31, 2023

TRADE PAYABLES

TRADE PAYABLES

NOTE 8 - TRADE PAYABLES

Trade payables are amounts billed to the Company by suppliers for goods and services in the ordinary course of business. All amounts have short-term repayment terms and vary by supplier.

XML 25 R15.htm IDEA: XBRL DOCUMENT

CONCENTRATION OF RISKS

3 Months Ended

Mar. 31, 2023

CONCENTRATION OF RISKS

CONCENTRATION OF RISKS

NOTE 9 - CONCENTRATION OF RISKS

a) Major customers

During the period, the Company did not have any material recognizable major customers accounted for 10% or more of the Company’s revenue for the financial period ended March 31, 2023 and 2022.

b) Major suppliers

For month ended March 31, 2023 and 2022, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at year ended are presented as follows:

	2023		2022		2023			2022			2023		2022
	Purchase				Percentage of purchases							Accounts payable trade
Vendor A	$	410,208	$	504,906		20.43	%		18.89	%	$	408,334	$	502,559
Vendor B	$	314,739	$	333,751		15.67	%		12.49	%	$	313,300	$	332,200
Vendor C	$	213,965	$	449,494		10.65	%		16.82	%	$	199,312	$	178,749
	$	938,912	$	1,288,151		46.75	%		48.20	%	$	920,946	$	1,013,508

XML 26 R16.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY

3 Months Ended

Mar. 31, 2023

STOCKHOLDERS EQUITY

STOCKHOLDERS' EQUITY

NOTE 10 - STOCK HOLDERS’ EQUITY

As at March 31, 2023 and 2022, the Company issued and outstanding common stock is 173,718,152 and 171,218,152 shares respectively.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

SEGMENTED INFORMATION

3 Months Ended

Mar. 31, 2023

SEGMENTED INFORMATION

SEGMENTED INFORMATION

NOTE 11 - SEGMENTED INFORMATION

At March 31, 2023, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

		BioNexus Gene Lab Corp. (a Wyoming company)





	100%			100%

Bionexus Gene Lab Sdn Bhd (a Malaysia company)			Chemrex Corporation Sdn Bhd (a Malaysia Company)

For the quarter ended March 31, 2023, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

	BioNexus Malaysia			Chemrex			BGLC			Total
	Three months ended March 31, 2023

REVENUE	$	7,436		$	2,369,769		$	-		$	2,377,205

COST OF REVENUE		(5,347	)		(2,002,961	)		-			(2,008,308	)

GROSS /PROFIT		2,089			366,808			-			368,897

OTHER INCOME		1,126			116,218			-			117,344

OPERATING EXPENSES
General and administrative		(46,255	)		(383,177	)		(107,440	)		(536,872	)

(LOSS)/PROFIT FROM OPERATIONS		(43,040	)		99,849			(107,440	)		(50,631	)

FINANCE COSTS		(666	)		(1,779	)		-			(2,445	)

(LOSS)/PROFIT BEFORE TAX		(43,706	)		98,070			(107,440	)		(53,076	)

Tax expense		-			(15,990	)		-			(15,990	)

NET (LOSS)/PROFIT	$	(43,706	)	$	82,080		$	(107,440	)	$	(69,066	)

	BioNexus Malaysia			Chemrex			BGLC			Total
	Three months ended March 31, 2022
REVENUE	$	24,269		$	3,004,676		$	-		$	3,028,945

COST OF REVENUE		(8,038	)		(2,664,574	)		-			(2,672,612	)

GROSS PROFIT		16,231			340,102			-			356,333

OTHER INCOME		2,076			44,306			12			46,394

OPERATING EXPENSES
General and administrative		(44,042	)		(297,769	)		(26,225	)		(368,036	)

(LOSS)/PROFIT FROM OPERATIONS		(25,735	)		86,639			(26,213	)		34,691

FINANCE COSTS		(799	)		(2,527	)		-			(3,326	)

PROFIT/(LOSS) BEFORE TAX		(52,269	)		170,751			(52,426	)		31,365

Tax expense		-			(14,299	)		-			(14,299	)

NET PROFIT/(LOSS)	$	(52,269	)	$	502,730		$	(52,426	)	$	17,066

	As of March 31, 2023 and December 31, 2022
	Total Assets				Total Liabilities
	2023		2022		2023		2022

BGLC & Bionexus	$	509,574	$	677,477	$	93,034	$	108,390
Chemrex		7,677,067		8,062,685		1,536,699		1,966,759
TOTAL		8,186,641		8,740,162		1,629,733		2,075,149

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

XML 28 R18.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2023

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

NOTE 12 - SUBSEQUENT EVENTS

XML 29 R19.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2023

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

Basis of consolidation

Use of estimates

Cash and cash equivalents

Trade receivables

Inventories

Leases

Property, plant and equipment

The principal annual rates used are as follows:

Categories	Principal Annual Rates
Air conditioner		20	%
Buildings		2	%
Computer and software		33	%
Equipment		20	%
Furniture and fittings	10% to 20		%
Lab Equipment		10	%
Motor vehicle	10% to 20		%
Office equipment		20	%
Renovation	10% to 20		%
Signboard		10	%

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.

Impairment of long-lived assets

Revenue recognition

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

·	identify the contract with a customer;
·	identify the performance obligations in the contract;
·	determine the transaction price;
·	allocate the transaction price to performance obligations in the contract; and
·	recognize revenue as the performance obligation is satisfied.

The Company records revenue at point in time which is recognized upon goods delivered or services rendered.

Shipping and handling fees

Comprehensive income

Income taxes

Net earnings or loss per share

Foreign currencies translation

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year:

	March 31,		December 31,
	2023		2022
Period ended March 31, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate		4.4170		4.3900

	January 1, 2023 to March 31, 2023		January 1, 2022 to March 31, 2022
3 months average US$1: MYR exchange rate		4.3968		4.1938

Related parties

Fair value of financial instruments

·	Level 1: Observable inputs such as quoted prices in active markets;

·	Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

·	Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions

Recent accounting pronouncements

XML 30 R20.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2023

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of Principal Annual Rates

Categories	Principal Annual Rates
Air conditioner		20	%
Buildings		2	%
Computer and software		33	%
Equipment		20	%
Furniture and fittings	10% to 20		%
Lab Equipment		10	%
Motor vehicle	10% to 20		%
Office equipment		20	%
Renovation	10% to 20		%
Signboard		10	%

Schedule of Exchange Rates

	March 31,		December 31,
	2023		2022
Period ended March 31, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate		4.4170		4.3900

	January 1, 2023 to March 31, 2023		January 1, 2022 to March 31, 2022
3 months average US$1: MYR exchange rate		4.3968		4.1938

XML 31 R21.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

3 Months Ended

Mar. 31, 2023

INCOME TAXES

Schedule of Deferred Tax Assets and Liabilities

	As of
	March 31,			December 31,
	2023			2022
Tax Recoverable
Local	$	-		$	-
Foreign, representing Malaysia		(27,823	)		(31,551	)
Tax Recoverable		(27,823	)		(31,551	)

Income tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		-			-
Income tax payables		-			-

Deferred tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		30,678			30,866
Deferred tax liabilities		30,678			30,866
Total		2,855			(685	)

XML 32 R22.htm IDEA: XBRL DOCUMENT

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2023

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

Schedule of operating lease right of use assets

Operating lease right of use assets as follows:	As of
	March 31,			December 31,
	2023			2022
Balance as of beginning of the year	$	55,730		$	41,090
Add: Addition of lease liabilities		-			32,281
Less: Amortization		(3,954	)		(15,534	)
Foreign translation differences		(341	)		(2,106	)
Balance	$	51,436		$	55,730

Schedule of the operating lease liability

Operating lease liabilities as follows:
	March 31,			December 31,
	2023			2022
Balance as of beginning of the year	$	56,775		$	42,909
Add: Addition of lease liabilities		-			30,770
Less: gross repayment		(4,875	)		(19,618	)
Add: imputed interest		855			4,913
Foreign translation differences		(346	)		(2,199	)
Balance as of end of the year		52,409			56,775
Less: lease liability current portion		(16,733	)		(16,569	)
Lease liability non-current portion	$	35,676		$	40,206

Schedule of Amortization of Right of Use

Other information:	As of
	March 31, 2023			December 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating lease	$	(4,366	)	$	(126,686	)
Right of use assets obtained in exchange for operating lease liabilities		51,436			55,730
Remaining lease term for operating lease (years)		3.75			4
Weighted average discount rate for operating lease	$	6.40	%	$	6.40	%

XML 33 R23.htm IDEA: XBRL DOCUMENT

PROPERTY PLANT AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2023

PROPERTY PLANT AND EQUIPMENT

Schedule of Plant and Equipment

	As of
	March 31,			December 31,
	2023			2022
Air conditioner	$	1,124		$	1,124
Computer and software		2,516			2,516
Equipment		60,525			60,525
Furniture and fittings		87,122			87,122
Lab equipment		320,102			320,102
Land and buildings		1,506,969			1,506,969
Motor vehicle		137,914			137,914
Office equipment		38,213			38,213
Renovation		107,414			107,414
Signboard		806			704
		2,262,705			2,262,603
(Less): Accumulated depreciation		(611,214	)		(590,317	)
Add: Foreign translation differences		(169,724	)		(133,982	)
Property, plant and equipment, net	$	1,481,767		$	1,511,708

XML 34 R24.htm IDEA: XBRL DOCUMENT

OTHER INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2023

OTHER INVESTMENTS

Schedule of Other Investments

	As of
	March 31,			December 31,
	2023			2022
As of beginning of the year	$	1,150,898		$	749,027
Addition during the year		13,646			511,706
Disposal during the year		-			(1,776	)
Fair value loss		37,399			(70,628	)
Foreign exchange translation		(7,268	)		(37,431	)
As of end of the year	$	1,194,675		$	1,150,898

	As of
	March 31,		December 31,
	2023		2022
Investment in quoted shares:
Malaysia		689,531		659,970
Singapore		94,757		101,426
Hong Kong		410,387		389,502
	$	1,194,675	$	1,150,898

XML 35 R25.htm IDEA: XBRL DOCUMENT

CONCENTRATION OF RISKS (Tables)

3 Months Ended

Mar. 31, 2023

CONCENTRATION OF RISKS

Schedule of Major suppliers Cost Of Sales

	2023		2022		2023			2022			2023		2022
	Purchase				Percentage of purchases							Accounts payable trade
Vendor A	$	410,208	$	504,906		20.43	%		18.89	%	$	408,334	$	502,559
Vendor B	$	314,739	$	333,751		15.67	%		12.49	%	$	313,300	$	332,200
Vendor C	$	213,965	$	449,494		10.65	%		16.82	%	$	199,312	$	178,749
	$	938,912	$	1,288,151		46.75	%		48.20	%	$	920,946	$	1,013,508

XML 36 R26.htm IDEA: XBRL DOCUMENT

SEGMENTED INFORMATION (Tables)

3 Months Ended

Mar. 31, 2023

SEGMENTED INFORMATION

Schedule of Segmented Revenue and Net Profit/(Loss)

	BioNexus Malaysia			Chemrex			BGLC			Total
	Three months ended March 31, 2023

REVENUE	$	7,436		$	2,369,769		$	-		$	2,377,205

COST OF REVENUE		(5,347	)		(2,002,961	)		-			(2,008,308	)

GROSS /PROFIT		2,089			366,808			-			368,897

OTHER INCOME		1,126			116,218			-			117,344

OPERATING EXPENSES
General and administrative		(46,255	)		(383,177	)		(107,440	)		(536,872	)

(LOSS)/PROFIT FROM OPERATIONS		(43,040	)		99,849			(107,440	)		(50,631	)

FINANCE COSTS		(666	)		(1,779	)		-			(2,445	)

(LOSS)/PROFIT BEFORE TAX		(43,706	)		98,070			(107,440	)		(53,076	)

Tax expense		-			(15,990	)		-			(15,990	)

NET (LOSS)/PROFIT	$	(43,706	)	$	82,080		$	(107,440	)	$	(69,066	)

	BioNexus Malaysia			Chemrex			BGLC			Total
	Three months ended March 31, 2022
REVENUE	$	24,269		$	3,004,676		$	-		$	3,028,945

COST OF REVENUE		(8,038	)		(2,664,574	)		-			(2,672,612	)

GROSS PROFIT		16,231			340,102			-			356,333

OTHER INCOME		2,076			44,306			12			46,394

OPERATING EXPENSES
General and administrative		(44,042	)		(297,769	)		(26,225	)		(368,036	)

(LOSS)/PROFIT FROM OPERATIONS		(25,735	)		86,639			(26,213	)		34,691

FINANCE COSTS		(799	)		(2,527	)		-			(3,326	)

PROFIT/(LOSS) BEFORE TAX		(52,269	)		170,751			(52,426	)		31,365

Tax expense		-			(14,299	)		-			(14,299	)

NET PROFIT/(LOSS)	$	(52,269	)	$	502,730		$	(52,426	)	$	17,066

	As of March 31, 2023 and December 31, 2022
	Total Assets				Total Liabilities
	2023		2022		2023		2022

BGLC & Bionexus	$	509,574	$	677,477	$	93,034	$	108,390
Chemrex		7,677,067		8,062,685		1,536,699		1,966,759
TOTAL		8,186,641		8,740,162		1,629,733		2,075,149

XML 37 R27.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)	3 Months Ended
	Mar. 31, 2023 shares
BGS Lab Sdn. Bhd [Member]
Business acquisition, business operation description	The principal office address is Unit 02 Level 10, Tower B, Vertical Business Suite, No. 8 Jalan Kerinchi, Bangsar South, 59200 Kuala Lumpur, Malaysia, our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. We also have a blood collection center located at 1st floor, Lifecare Medical Centre, Kuala Lumpur, Malaysia.
Business Acquisition, Effective Date of Acquisition	Aug. 23, 2017
Chemrex Corporation Sdn. Bhd. [Member]
Business aquisition, shares converted	68,487,261

XML 38 R28.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Mar. 31, 2023
Equipment [Member]
Principal Annual Rates	20.00%
Air Conditioner [Member]
Principal Annual Rates	20.00%
Buildings [Member]
Principal Annual Rates	2.00%
Computer and Software [Member]
Principal Annual Rates	33.00%
Furniture and Fittings [Member] \| Maximum [Member]
Principal Annual Rates	20.00%
Furniture and Fittings [Member] \| Minimum [Member]
Principal Annual Rates	10.00%
Lab Equipment [Member]
Principal Annual Rates	10.00%
Motor Vehicle [Member] \| Maximum [Member]
Principal Annual Rates	20.00%
Motor Vehicle [Member] \| Minimum [Member]
Principal Annual Rates	10.00%
Office Equipment [Member]
Principal Annual Rates	20.00%
Renovation [Member] \| Maximum [Member]
Principal Annual Rates	20.00%
Renovation [Member] \| Minimum [Member]
Principal Annual Rates	10.00%
Signboard [Member]
Principal Annual Rates	10.00%

XML 39 R29.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	3 Months Ended		12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Period ended March 31, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate	4.4170		4.3900
3 months average US$1: MYR exchange rate	4.3968	4.1938

XML 40 R30.htm IDEA: XBRL DOCUMENT

TRADE RECEIVABLES (Details Narrative)	3 Months Ended
TRADE RECEIVABLES (Details Narrative)	Mar. 31, 2023
TRADE RECEIVABLES
Non-interest bearing	The normal trade credit term is generally on 30 days to 90 days term.
Interest rate	6.00%

XML 41 R31.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Tax Recoverable	$ (27,823)	$ (31,551)
Income tax liabilities	0	0
Deferred tax liabilities	30,678	30,866
Total	2,855	(685)
Malaysia [Member]
Tax Recoverable	(27,823)	(31,551)
Income tax liabilities	0	0
Deferred tax liabilities	30,678	30,866
Local [Member]
Tax Recoverable	0	0
Income tax liabilities	0	0
Deferred tax liabilities	$ 0	$ 0

XML 42 R32.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details Narrative) - Malaysia [Member]	3 Months Ended
INCOME TAXES (Details Narrative) - Malaysia [Member]	Mar. 31, 2023
Statutory income tax rate	24.00%
Statutory income tax rate, description	Under the amendment of Income Tax Act 1967 by the Finance Act 2020 and with effect from year of assessment 2020, companies with paid-up capital of RM2.5 million or less, and with annual business income of not more than RM50 million are subject to Small and Medium Enterprise Corporate Tax at 17% on chargeable income up to RM600,000 (2021: RM600,000) except for companies with investment holding nature or companies does not have gross income from business sources are subject to corporate tax at 24% on chargeable income.

XML 43 R33.htm IDEA: XBRL DOCUMENT

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES
Beginning Balance	$ 55,730	$ 41,090
Add;Addition of lease liabilities	0	32,281
Less: Amortization	(3,954)	(15,534)
Foreign translation differences	(341)	(2,106)
Ending Balance	$ 51,436	$ 55,730

XML 44 R34.htm IDEA: XBRL DOCUMENT

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 1) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Foreign translation differences	$ (341)	$ (2,106)
Lease liabilities non-current portion	35,676	40,206
Operating lease liability [Member]
Beginning Balance	56,775	42,909
Add: Addition of lease liabilities	0	30,770
Less: gross repayment	(4,875)	(19,618)
Add: imputed interest	855	4,913
Foreign translation differences	(346)	(2,199)
Ending Balance	52,409	56,775
Less: lease liabilities current portion	(16,733)	(16,569)
Lease liabilities non-current portion	$ 35,676	$ 40,206

XML 45 R35.htm IDEA: XBRL DOCUMENT

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 3) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating lease	$ (4,366)	$ (126,686)
Right of use assets obtained in exchange for operating lease liabilities	$ 51,436	$ 55,730
Remaining lease term for operating lease (years)	3 years 9 months	4 years
Weighted average discount rate for operating lease	6.40%	6.40%

XML 46 R36.htm IDEA: XBRL DOCUMENT

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Amortization of right of use asset	$ 3,972	$ 4,341
Lease expenses	$ 855		$ 4,913
Malayan Banking [Member]
Rental payment discount rate	6.40%

XML 47 R37.htm IDEA: XBRL DOCUMENT

PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Total Plant and equipment	$ 2,262,705	$ 2,262,603
Less: Accumulated amortization	(611,214)	(590,317)
Add: Foreign translation differences	(169,724)	(133,982)
Property, plant and equipment, net	1,481,767	1,511,708
Equipment [Member]
Total Plant and equipment	60,525	60,525
Air Conditioner [Member]
Total Plant and equipment	1,124	1,124
Computer and Software [Member]
Total Plant and equipment	2,516	2,516
Lab Equipment [Member]
Total Plant and equipment	320,102	320,102
Office Equipment [Member]
Total Plant and equipment	38,213	38,213
Signboard [Member]
Total Plant and equipment	806	704
Furniture and fittings [Member]
Total Plant and equipment	87,122	87,122
Land and buildings [Member]
Total Plant and equipment	1,506,969	1,506,969
Motor Vehicle [Member]
Total Plant and equipment	137,914	137,914
Renovation [Member]
Total Plant and equipment	$ 107,414	$ 107,414

XML 48 R38.htm IDEA: XBRL DOCUMENT

PROPERTY PLANT AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
PROPERTY PLANT AND EQUIPMENT
Depreciation expense	$ 20,897	$ 22,307

XML 49 R39.htm IDEA: XBRL DOCUMENT

OTHER INVESTMENTS (Details) - USD ($)	3 Months Ended	12 Months Ended
OTHER INVESTMENTS (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
OTHER INVESTMENTS
As of beginning of the year	$ 1,150,898	$ 749,027
Addition during the year	13,646	511,706
Disposal during the year	0	(1,776)
Fair value loss	37,399	(70,628)
Foreign exchange translation	(7,268)	(37,431)
As of end of the year	$ 1,194,675	$ 1,150,898

XML 50 R40.htm IDEA: XBRL DOCUMENT

OTHER INVESTMENTS (Details 1) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Other investment	$ 1,194,675	$ 1,150,898
Malaysia [Member]
Other investment	689,531	659,970
Singapore [Member]
Other investment	94,757	101,426
Hong Kong [Member]
Other investment	$ 410,387	$ 389,502

XML 51 R41.htm IDEA: XBRL DOCUMENT

CONCENTRATION OF RISKS (Details) - USD ($)	3 Months Ended
CONCENTRATION OF RISKS (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Concentration of risk purchase	$ 938,912	$ 1,288,151
Percentage of purchases	46.75%	48.20%
Accounts payable trade	$ 920,946	$ 1,013,508
Vendor A [Member]
Concentration of risk purchase	$ 410,208	$ 504,906
Percentage of purchases	20.43%	18.89%
Accounts payable trade	$ 408,334	$ 502,559
Vendor B [Member]
Concentration of risk purchase	$ 314,739	$ 333,751
Percentage of purchases	15.67%	12.49%
Accounts payable trade	$ 313,300	$ 332,200
Vendor C [Member]
Concentration of risk purchase	$ 213,965	$ 449,494
Percentage of purchases	10.65%	16.82%
Accounts payable trade	$ 199,312	$ 178,749

XML 52 R42.htm IDEA: XBRL DOCUMENT

CONCENTRATION OF RISKS (Details Narrative)	3 Months Ended
CONCENTRATION OF RISKS (Details Narrative)	Mar. 31, 2023	Mar. 31, 2022
Concentration of risk of credit risk	46.75%	48.20%
Major Customer [Member]
Concentration of risk of credit risk	10.00%	10.00%
Major Suppliers [Member]
Concentration of risk of credit risk	10.00%	10.00%

XML 53 R43.htm IDEA: XBRL DOCUMENT

STOCK HOLDERS EQUITY (Details Narrative) - shares	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
STOCKHOLDERS EQUITY
Common stock, shares issued	173,718,152		171,218,152
Common stock, shares outstanding	173,718,152	173,718,152	171,218,152

XML 54 R44.htm IDEA: XBRL DOCUMENT

SEGMENTED INFORMATION (Details) - USD ($)	3 Months Ended
SEGMENTED INFORMATION (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
REVENUE	$ 2,377,205	$ 3,028,945
COST OF REVENUE	(2,008,308)	(2,672,612)
GROSS PROFIT	368,897	356,333
OTHER INCOME	117,344	46,394
General and administrative	(536,872)	(368,036)
(LOSS)/PROFIT FROM OPERATIONS	(50,631)	34,691
FINANCE COSTS	(2,445)	(3,326)
(LOSS)/PROFIT BEFORE TAX	(53,076)	31,365
Tax expense	(15,990)	(14,299)
Net (loss)/profit	(69,066)	17,066
FINANCE COSTS	2,445	3,326
BioNexus Malaysia [Member]
REVENUE	7,436	24,269
COST OF REVENUE	(5,347)	(8,038)
GROSS PROFIT	2,089	16,231
OTHER INCOME	1,126	2,076
General and administrative	(46,255)	(44,042)
(LOSS)/PROFIT FROM OPERATIONS	(43,040)	(25,735)
FINANCE COSTS	(666)	(799)
(LOSS)/PROFIT BEFORE TAX	(43,706)	(52,269)
Tax expense	0	0
Net (loss)/profit	(43,706)	(52,269)
FINANCE COSTS	666	799
Chemrex [Member]
REVENUE	2,369,769	3,004,676
COST OF REVENUE	(2,002,961)	(2,664,574)
GROSS PROFIT	366,808	340,102
OTHER INCOME	116,218	44,306
General and administrative	(383,177)	(297,769)
(LOSS)/PROFIT FROM OPERATIONS	99,849	86,639
FINANCE COSTS	(1,779)	(2,527)
(LOSS)/PROFIT BEFORE TAX	98,070	170,751
Tax expense	(15,990)	(14,299)
Net (loss)/profit	82,080	502,730
FINANCE COSTS	1,779	2,527
BGLC [Member]
REVENUE	0	0
COST OF REVENUE	0	0
GROSS PROFIT	0	0
OTHER INCOME	0	12
General and administrative	(107,440)	(26,225)
(LOSS)/PROFIT FROM OPERATIONS	(107,440)	(26,213)
FINANCE COSTS	0	0
(LOSS)/PROFIT BEFORE TAX	(107,440)	(52,426)
Tax expense	0	0
Net (loss)/profit	(107,440)	(52,426)
FINANCE COSTS	$ 0	$ 0

XML 55 R45.htm IDEA: XBRL DOCUMENT

SEGMENTED INFORMATION (Details 1) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Total assets	$ 8,186,641	$ 8,740,162
Total Liabilities	1,629,733	2,075,149
Chemrex [Member]
Total assets	7,677,067	8,062,685
Total Liabilities	1,536,699	1,966,759
BGLC & Bionexus [Member]
Total assets	509,574	677,477
Total Liabilities	$ 93,034	$ 108,390

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

+ Details

XML 56 bion_10q_htm.xml IDEA: XBRL DOCUMENT 0001737523 2023-01-01 2023-03-31 0001737523 bion:ChemrexMember 2023-03-31 0001737523 bion:ChemrexMember 2022-12-31 0001737523 bion:BglcAndBionexusMember 2023-03-31 0001737523 bion:BglcAndBionexusMember 2022-12-31 0001737523 bion:BglcMember 2022-01-01 2022-03-31 0001737523 bion:BglcMember 2023-01-01 2023-03-31 0001737523 bion:ChemrexMember 2022-01-01 2022-03-31 0001737523 bion:ChemrexMember 2023-01-01 2023-03-31 0001737523 bion:BionexusMalaysiaMember 2022-01-01 2022-03-31 0001737523 bion:BionexusMalaysiaMember 2023-01-01 2023-03-31 0001737523 bion:MajorSuppliersMember 2022-01-01 2022-03-31 0001737523 bion:MajorCustomerMember 2022-01-01 2022-03-31 0001737523 bion:MajorSuppliersMember 2023-01-01 2023-03-31 0001737523 bion:MajorCustomerMember 2023-01-01 2023-03-31 0001737523 bion:VendorCMember 2022-01-01 2022-03-31 0001737523 bion:VendorCMember 2023-01-01 2023-03-31 0001737523 bion:VendorBMember 2022-01-01 2022-03-31 0001737523 bion:VendorBMember 2023-01-01 2023-03-31 0001737523 bion:VendorAMember 2022-01-01 2022-03-31 0001737523 bion:VendorAMember 2023-01-01 2023-03-31 0001737523 bion:HongKongsMember 2023-03-31 0001737523 bion:HongKongsMember 2022-12-31 0001737523 bion:SingaporesMember 2023-03-31 0001737523 bion:SingaporesMember 2022-12-31 0001737523 bion:SignboardMember 2022-12-31 0001737523 bion:RenovationMember 2023-03-31 0001737523 bion:RenovationMember 2022-12-31 0001737523 us-gaap:OfficeEquipmentMember 2022-12-31 0001737523 bion:MotorVehicleMember 2023-03-31 0001737523 bion:MotorVehicleMember 2022-12-31 0001737523 bion:LandAndBuildingsMember 2023-03-31 0001737523 bion:LandAndBuildingsMember 2022-12-31 0001737523 bion:LabEquipmentMember 2022-12-31 0001737523 bion:FurnitureAndFittingsMember 2023-03-31 0001737523 bion:FurnitureAndFittingsMember 2022-12-31 0001737523 us-gaap:EquipmentMember 2022-12-31 0001737523 bion:ComputerAndSoftwareMember 2022-12-31 0001737523 bion:AirconditionerMember 2022-12-31 0001737523 bion:MalayanBankingMember 2023-01-01 2023-03-31 0001737523 bion:OperatingLeaseLiabilityMember 2023-03-31 0001737523 bion:OperatingLeaseLiabilityMember 2022-01-01 2022-12-31 0001737523 bion:OperatingLeaseLiabilityMember 2023-01-01 2023-03-31 0001737523 bion:OperatingLeaseLiabilityMember 2021-12-31 0001737523 bion:OperatingLeaseLiabilityMember 2022-12-31 0001737523 bion:MalaysiasMember 2023-01-01 2023-03-31 0001737523 bion:MalaysiasMember 2023-03-31 0001737523 bion:MalaysiasMember 2022-12-31 0001737523 bion:LocalMember 2023-03-31 0001737523 bion:LocalMember 2022-12-31 0001737523 2022-01-01 2022-12-31 0001737523 bion:SignboardMember 2023-03-31 0001737523 srt:MaximumMember bion:RenovationMember 2023-03-31 0001737523 srt:MinimumMember bion:RenovationMember 2023-03-31 0001737523 us-gaap:OfficeEquipmentMember 2023-03-31 0001737523 srt:MaximumMember bion:MotorVehicleMember 2023-03-31 0001737523 srt:MinimumMember bion:MotorVehicleMember 2023-03-31 0001737523 bion:LabEquipmentMember 2023-03-31 0001737523 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-03-31 0001737523 us-gaap:EquipmentMember 2023-03-31 0001737523 bion:ComputerAndSoftwareMember 2023-03-31 0001737523 bion:BuildingsMember 2023-03-31 0001737523 bion:AirconditionerMember 2023-03-31 0001737523 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-03-31 0001737523 bion:ChemrexCorporationSdnBhdMember 2023-01-01 2023-03-31 0001737523 bion:BGSLabSdnBhdMember 2023-01-01 2023-03-31 0001737523 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001737523 us-gaap:RetainedEarningsMember 2023-03-31 0001737523 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001737523 us-gaap:CommonStockMember 2023-03-31 0001737523 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001737523 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001737523 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001737523 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001737523 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001737523 us-gaap:RetainedEarningsMember 2022-12-31 0001737523 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001737523 us-gaap:CommonStockMember 2022-12-31 0001737523 2022-03-31 0001737523 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001737523 us-gaap:RetainedEarningsMember 2022-03-31 0001737523 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001737523 us-gaap:CommonStockMember 2022-03-31 0001737523 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001737523 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001737523 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001737523 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001737523 2021-12-31 0001737523 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001737523 us-gaap:RetainedEarningsMember 2021-12-31 0001737523 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001737523 us-gaap:CommonStockMember 2021-12-31 0001737523 2022-01-01 2022-03-31 0001737523 2022-12-31 0001737523 2023-03-31 0001737523 2023-05-09 iso4217:USD shares iso4217:USD shares pure 0001737523 false --12-31 Q1 2023

0.1 0.1

171218152

10-Q true 2023-03-31 false 333-229399 BIONEXUS GENE LAB CORP. WY 35-2604830 Unit 02, Level 10 Tower B, Avenue 3, The Vertical Business Suite II Bangsar South No. 8 Jalan Kerinchi Kuala Lumpur MY 59200 60 1221-26512 Yes Yes Non-accelerated Filer true true false false 173718152

406787

611849

1566425

1507015

2528746

2868364

29346

25240

27823

31551

899636

977807

5458763

6021826

51436

55730

1481767

1511708

1194675

1150898

2727878

2718336

8186641

8740162

1493774

1861015

37550

103370

16733

16569

15322

23123

1563379

2004077

35676

40206

30678

30866

66354

71072

1629733

2075149

300000000

173718152

30000000

300000000

173718152

30000000

10929574

10779574

-5011891

1087326

1156392

-448101

-409062

6556908

6665013

8186641

8740162

2377205

3028945

2008308

2672612

368897

356333

117344

46394

536872

368036

-50631

34691

2445

3326

-53076

31365

15990

14299

-69066

17066

-39039

-68776

-108105

-51710

-0.001 0.000 173718152 171218152

171218152

10779574

-5011891

1512358

-100262

7179779

17066

0 0 0 -68776 -68776

171218152

10779574

-5011891

1529424

-169038

7128069

173718152

10779574

-5011891

1156392

-409062

6665013

-69066

0 0 0 -39039 -39039

173718152

10779574

-5011891

1087326

-448101

6556908

-69066

17066

3972

4341

20897

22307

8692 7230

37399

-3779

-90292

40263

-78171

126988

-335512

-330316

0 67606

-433061

-208629

-7801

-30200

-77276

-4366

-5007

-3540

27924

-118297

-37839

13646

172172

8692

7230

102

32191

-5056

-197133

-22299

-44625

-145652

-279597

2118864

2123919

1973212

1844322

1566425 1237472 406787 606850 1973212 1844322

2445

3326

-12438

-41946

NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND BioNexus Gene Lab Corp. (the “Company”) was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, the Company acquired all the outstanding capital stock of BGS Lab Sdn. Bhd., a Malaysian corporation (“BioNexus Malaysia”). BioNexus Malaysia was incorporated in Malaysia on April 7, 2015 which it then subsequently changed its name to Bionexus Gene Lab Sdn. Bhd. The principal office address is Unit 02 Level 10, Tower B, Vertical Business Suite, No. 8 Jalan Kerinchi, Bangsar South, 59200 Kuala Lumpur, Malaysia, our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. We also have a blood collection center located at 1st floor, Lifecare Medical Centre, Kuala Lumpur, Malaysia. On December 31, 2020, the Company consummated its acquisition of Chemrex Corporation Sdn. Bhd. (“Chemrex”), pursuant to a Share Exchange Agreement by and among the Company, Chemrex and the Chemrex shareholders wherein the Company acquired all the issued and outstanding shares of capital stock of Chemrex from the Chemrex shareholders in exchange for 68,487,261 shares of common stock of the Company. The acquisition of Chemrex has been accounted for as a common control transaction as there is no change in the control over the assets acquired and liabilities assumed. The net assets are derecognized by the transferring entity (i.e. Chemrex) and recognized by the receiving entity (i.e. the Company). The difference between the consideration transferred and the carrying amounts of the net assets is recognized in equity. The financial statements of the receiving entity report the results of operations for the period in which the transfer occurs as though the transfer of net assets or exchange of equity interests had occurred at the beginning of the period. Results of operations for that period will thus comprise those of the previously separate entities combined from the beginning of the period to the date the transfer is completed and those of the combined operations from that date to the end of the period. The comparative financial statements were not adjusted retrospectively as Chemrex was not under common control during the comparative period. The corporate structure as at March 31, 2023 is depicted below: <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:70%"><tbody><tr style="height:15px"><td> </td><td> </td><td colspan="2" style="BORDER-TOP: #000000 1px solid; BORDER-RIGHT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> BioNexus Gene Lab Corp.(a Wyoming company) </td><td> </td><td> </td></tr><tr style="height:15px"><td style="width:16%;"> </td><td style="width:17%;"> </td><td style="BORDER-RIGHT: #000000 1px solid;width:17%;"> </td><td style="width:17%;"> </td><td style="width:16%;"> </td><td style="width:17%;"> </td></tr><tr style="height:15px"><td> </td><td> </td><td style="BORDER-RIGHT: #000000 1px solid;"> </td><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td style="BORDER-RIGHT: #000000 1px solid;"> </td><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="BORDER-BOTTOM: #000000 1px solid;"> </td><td style="BORDER-RIGHT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;"> </td><td style="BORDER-BOTTOM: #000000 1px solid;"> </td><td style="BORDER-BOTTOM: #000000 1px solid;"> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="BORDER-LEFT: #000000 1px solid;"> </td><td> </td><td> </td><td style="BORDER-RIGHT: #000000 1px solid;"> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="BORDER-LEFT: #000000 1px solid;"> 100%</td><td> </td><td> </td><td style="BORDER-RIGHT: #000000 1px solid;"> </td><td> 100%</td></tr><tr style="height:15px"><td/><td style="BORDER-LEFT: #000000 1px solid;"/><td> </td><td> </td><td style="BORDER-RIGHT: #000000 1px solid;"/><td/></tr><tr style="height:15px"><td colspan="2" style="BORDER-TOP: #000000 1px solid; BORDER-RIGHT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> Bionexus Gene Lab Sdn Bhd(a Malaysia company) </td><td> </td><td> </td><td colspan="2" style="BORDER-TOP: #000000 1px solid; BORDER-RIGHT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> Chemrex Corporation Sdn Bhd(a Malaysia Company) </td></tr></tbody></table>

2017-08-23

68487261

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes. <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Basis of presentation</td></tr></tbody></table> The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Basis of consolidation</td></tr></tbody></table> The condensed consolidated financial statements include the accounts of Bionexus Gene Lab Corp. and its subsidiaries. All significant inter-company balances and transactions within the Company have been eliminated upon consolidation. <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Use of estimates</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:96%;">In preparing these condensed consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the periods reported. Actual results may differ from these estimates.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="width:92%;vertical-align:top;">Cash and cash equivalents</td></tr></tbody></table> Cash and cash equivalents represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of Three months or less as of the purchase date of such investments. <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="width:92%;vertical-align:top;">Trade receivables</td></tr></tbody></table> Trade receivables are recorded at the invoiced amount and do not bear interest. Management reviews the adequacy of the allowance for impairment on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to adjust in the allowance when it is considered necessary. Trade balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="width:92%;vertical-align:top;">Inventories</td></tr></tbody></table> Inventories consisting of products available for sell, are stated at the lower of cost or market value. Cost of inventory is determined using the first-in, first-out (FIFO) method. Inventory reserve is recorded to write down the cost of inventory to the estimated market value due to slow-moving merchandise and damaged goods, which is dependent upon factors such as historical and forecasted consumer demand, and promotional environment. The Company takes ownership, risks and rewards of the products purchased. Write downs are recorded in cost of revenues in the Statement of Operations and Comprehensive Income. <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Leases</td></tr></tbody></table> Prior to January 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases. Effective January 1, 2019, the Company adopted the guidance of ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The Company adopted ASC 842 using a modified retrospective approach. As a result, the comparative financial information has not been updated and the required disclosures prior to the date of adoption have not been updated and continue to be reported under the accounting standards in effect for those periods.<table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Property, plant and equipment</td></tr></tbody></table> Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on the straight-line basis to write off the cost over the following expected useful lives of the assets concerned. The principal annual rates used are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Categories</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">PrincipalAnnual Rates</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Air conditioner</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Buildings</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Computer and software</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Furniture and fittings</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">10% to 20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"> %</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Lab Equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Motor vehicle</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">10% to 20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"> %</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Office equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Renovation</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">10% to 20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"> %</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Signboard</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> Leasehold lands are depreciated over the period of lease term. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Freehold land is not depreciated. Property, plant and equipment under construction are not depreciated until the assets are ready for their intended use. Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized. When properties are disposed, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place. Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.<table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Impairment of long-lived assets</td></tr></tbody></table> Long-lived assets primarily include goodwill, intangible assets and property, plant and equipment. In accordance with the provision of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, the Company generally conducts its annual impairment evaluation to its long-lived assets, usually in the fourth quarter of each fiscal year, or more frequently if indicators of impairment exist, such as a significant sustained change in the business climate. The recoverability of long-lived assets is measured at the lowest level group. If the total of the expected undiscounted future net cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. There has been no impairment charge for the years presented. <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Revenue recognition</td></tr></tbody></table> Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">identify the contract with a customer;</td></tr><tr style="height:15px"><td style="vertical-align:top;">·</td><td style="vertical-align:top;">identify the performance obligations in the contract;</td></tr><tr style="height:15px"><td style="vertical-align:top;">·</td><td style="vertical-align:top;">determine the transaction price;</td></tr><tr style="height:15px"><td style="vertical-align:top;">·</td><td style="vertical-align:top;">allocate the transaction price to performance obligations in the contract; and</td></tr><tr style="height:15px"><td style="vertical-align:top;">·</td><td style="vertical-align:top;">recognize revenue as the performance obligation is satisfied.</td></tr></tbody></table> The Company records revenue at point in time which is recognized upon goods delivered or services rendered. <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="width:92%;vertical-align:top;">Shipping and handling fees</td></tr></tbody></table> Shipping and handling fees, if billed to customers, are included in revenue. Shipping and handling fees associated with inbound and outbound freight are expensed as incurred and included in selling and distribution expenses.<table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Comprehensive income</td></tr></tbody></table> ASC Topic 220, “Comprehensive Income” establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying statements of stockholders’ equity consists of changes in unrealized gains and losses on foreign currency translation and cumulative net change in the fair value of available-for-sale investments held at the balance sheet date. This comprehensive income is not included in the computation of income tax expense or benefit. <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Income taxes</td></tr></tbody></table> Income taxes are determined in accordance with the provisions of ASC Topic 740, “Income Taxes” (“ASC Topic 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclosed in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. The Company conducts major businesses in Malaysia and is subject to tax in their own jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities. <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Net earnings or loss per share</td></tr></tbody></table> The Company calculates net earnings or loss per share in accordance with ASC Topic 260 “Earnings per share”. Basic earnings or loss per share is computed by dividing the net earnings or loss by the weighted average number of common shares outstanding during the period. Diluted earnings or loss per share is computed similar to basic earnings or loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.<table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Foreign currencies translation</td></tr></tbody></table> Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations. The functional currency of the Company is the United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. In addition, the subsidiaries maintain its books and record in a local currency, Malaysian Ringgit (“MYR” or “RM”), which is functional currency as being the primary currency of the economic environment in which the subsidiaries operate. In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income. Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Period ended March 31, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.4170</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.3900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">January 1, 2023 to March 31,2023</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">January 1, 2022 to March 31,2022</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">3 months average US$1: MYR exchange rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.3968</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.1938</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Related parties</td></tr></tbody></table> Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.<table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Fair value of financial instruments</td></tr></tbody></table> The carrying value of the Company’s financial instruments: cash and cash equivalents, trade receivable, deposits and other receivables, amount due to related parties and other payables approximate at their fair values because of the short-term nature of these financial instruments. The Company also follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a six-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;">·</td><td>Level 1: Observable inputs such as quoted prices in active markets;</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td>·</td><td>Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;">·</td><td style="width:92%;vertical-align:top;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions</td></tr></tbody></table> As of March 31, 2023, and December 31, 2022, the Company did not have any nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements, at least annually, on a recurring basis, nor did the Company have any assets or liabilities measured at fair value on a non-recurring basis. <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="width:92%;vertical-align:top;">Recent accounting pronouncements</td></tr></tbody></table> The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations. In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. The amendments in this Update address those stakeholders’ concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its consolidated financial statements. FASB issues various Accounting Standards Updates relating to the treatment and recording of certain accounting transactions. On June 10, 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2014-10, Development Stage Entities (Topic 915) Elimination of Certain Financial Reporting Requirements, including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, which eliminates the concept of a development stage entity (DSE) entirely from current accounting guidance. The Company has elected adoption of this standard, which eliminates the designation of DSEs and the requirement to disclose results of operations and cash flows since inception.

The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

The condensed consolidated financial statements include the accounts of Bionexus Gene Lab Corp. and its subsidiaries. All significant inter-company balances and transactions within the Company have been eliminated upon consolidation.

In preparing these condensed consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the periods reported. Actual results may differ from these estimates.

Cash and cash equivalents represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of Three months or less as of the purchase date of such investments.

Trade receivables are recorded at the invoiced amount and do not bear interest. Management reviews the adequacy of the allowance for impairment on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to adjust in the allowance when it is considered necessary. Trade balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

Inventories consisting of products available for sell, are stated at the lower of cost or market value. Cost of inventory is determined using the first-in, first-out (FIFO) method. Inventory reserve is recorded to write down the cost of inventory to the estimated market value due to slow-moving merchandise and damaged goods, which is dependent upon factors such as historical and forecasted consumer demand, and promotional environment. The Company takes ownership, risks and rewards of the products purchased. Write downs are recorded in cost of revenues in the Statement of Operations and Comprehensive Income.

Prior to January 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases. Effective January 1, 2019, the Company adopted the guidance of ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The Company adopted ASC 842 using a modified retrospective approach. As a result, the comparative financial information has not been updated and the required disclosures prior to the date of adoption have not been updated and continue to be reported under the accounting standards in effect for those periods.

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on the straight-line basis to write off the cost over the following expected useful lives of the assets concerned. The principal annual rates used are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Categories</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">PrincipalAnnual Rates</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Air conditioner</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Buildings</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Computer and software</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Furniture and fittings</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">10% to 20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"> %</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Lab Equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Motor vehicle</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">10% to 20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"> %</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Office equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Renovation</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">10% to 20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"> %</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Signboard</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> Leasehold lands are depreciated over the period of lease term. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Freehold land is not depreciated. Property, plant and equipment under construction are not depreciated until the assets are ready for their intended use. Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized. When properties are disposed, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place. Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Categories</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">PrincipalAnnual Rates</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Air conditioner</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Buildings</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Computer and software</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Furniture and fittings</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">10% to 20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"> %</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Lab Equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Motor vehicle</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">10% to 20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"> %</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Office equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Renovation</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">10% to 20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"> %</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Signboard</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> 0.20 0.02 0.33 0.20 0.10 0.20 0.10 0.10 0.20 0.20 0.10 0.20 0.10

Long-lived assets primarily include goodwill, intangible assets and property, plant and equipment. In accordance with the provision of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, the Company generally conducts its annual impairment evaluation to its long-lived assets, usually in the fourth quarter of each fiscal year, or more frequently if indicators of impairment exist, such as a significant sustained change in the business climate. The recoverability of long-lived assets is measured at the lowest level group. If the total of the expected undiscounted future net cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. There has been no impairment charge for the years presented.

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">identify the contract with a customer;</td></tr><tr style="height:15px"><td style="vertical-align:top;">·</td><td style="vertical-align:top;">identify the performance obligations in the contract;</td></tr><tr style="height:15px"><td style="vertical-align:top;">·</td><td style="vertical-align:top;">determine the transaction price;</td></tr><tr style="height:15px"><td style="vertical-align:top;">·</td><td style="vertical-align:top;">allocate the transaction price to performance obligations in the contract; and</td></tr><tr style="height:15px"><td style="vertical-align:top;">·</td><td style="vertical-align:top;">recognize revenue as the performance obligation is satisfied.</td></tr></tbody></table> The Company records revenue at point in time which is recognized upon goods delivered or services rendered.

Shipping and handling fees, if billed to customers, are included in revenue. Shipping and handling fees associated with inbound and outbound freight are expensed as incurred and included in selling and distribution expenses.

ASC Topic 220, “Comprehensive Income” establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying statements of stockholders’ equity consists of changes in unrealized gains and losses on foreign currency translation and cumulative net change in the fair value of available-for-sale investments held at the balance sheet date. This comprehensive income is not included in the computation of income tax expense or benefit.

Income taxes are determined in accordance with the provisions of ASC Topic 740, “Income Taxes” (“ASC Topic 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclosed in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. The Company conducts major businesses in Malaysia and is subject to tax in their own jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

The Company calculates net earnings or loss per share in accordance with ASC Topic 260 “Earnings per share”. Basic earnings or loss per share is computed by dividing the net earnings or loss by the weighted average number of common shares outstanding during the period. Diluted earnings or loss per share is computed similar to basic earnings or loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations. The functional currency of the Company is the United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. In addition, the subsidiaries maintain its books and record in a local currency, Malaysian Ringgit (“MYR” or “RM”), which is functional currency as being the primary currency of the economic environment in which the subsidiaries operate. In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income. Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Period ended March 31, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.4170</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.3900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">January 1, 2023 to March 31,2023</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">January 1, 2022 to March 31,2022</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">3 months average US$1: MYR exchange rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.3968</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.1938</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

The carrying value of the Company’s financial instruments: cash and cash equivalents, trade receivable, deposits and other receivables, amount due to related parties and other payables approximate at their fair values because of the short-term nature of these financial instruments. The Company also follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a six-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;">·</td><td>Level 1: Observable inputs such as quoted prices in active markets;</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td>·</td><td>Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;">·</td><td style="width:92%;vertical-align:top;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions</td></tr></tbody></table> As of March 31, 2023, and December 31, 2022, the Company did not have any nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements, at least annually, on a recurring basis, nor did the Company have any assets or liabilities measured at fair value on a non-recurring basis.

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations. In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. The amendments in this Update address those stakeholders’ concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its consolidated financial statements. FASB issues various Accounting Standards Updates relating to the treatment and recording of certain accounting transactions. On June 10, 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2014-10, Development Stage Entities (Topic 915) Elimination of Certain Financial Reporting Requirements, including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, which eliminates the concept of a development stage entity (DSE) entirely from current accounting guidance. The Company has elected adoption of this standard, which eliminates the designation of DSEs and the requirement to disclose results of operations and cash flows since inception.

NOTE 3 - TRADE RECEIVABLES The Company has performed an analysis on all its trade receivables and determined that all amounts are collectible by the Company. As such, trade receivables are reflected as a current asset and no allowance for impairment has been recorded as of March 31, 2023 and December, 31, 2022. The Company’s trade receivables consist of receivable from customers which are unrelated to the Company. The account receivables are interest bearing at a rate of 6% per annum on a case to case basis for customers that exceeded credit term. The normal trade credit term is generally on 30 days to 90 days term.

0.06

The normal trade credit term is generally on 30 days to 90 days term.

NOTE 4 - INCOME TAXES The Company provides for income taxes under ASC 740, “Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statements and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. It also requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Provision for income taxes consisted of the following: United States of AmericaThe Company is registered in the State of Wyoming and is subject to the tax laws of the United States of America. MalaysiaBioNexus Malaysia and Chemrex are both subject to Malaysia Corporate Tax, which is charged at the statutory income tax rate range is 24% on its assessable income. Under the amendment of Income Tax Act 1967 by the Finance Act 2020 and with effect from year of assessment 2020, companies with paid-up capital of RM2.5 million or less, and with annual business income of not more than RM50 million are subject to Small and Medium Enterprise Corporate Tax at 17% on chargeable income up to RM600,000 (2021: RM600,000) except for companies with investment holding nature or companies does not have gross income from business sources are subject to corporate tax at 24% on chargeable income. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">As of</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Tax Recoverable</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Local</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Foreign, representing Malaysia</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(27,823</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(31,551</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tax Recoverable</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(27,823</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(31,551</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income tax liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Local</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign, representing Malaysia</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Income tax payables</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Deferred tax liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Local</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Foreign, representing Malaysia</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">30,678</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">30,866</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Deferred tax liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">30,678</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">30,866</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,855</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(685</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table>

0.24

Under the amendment of Income Tax Act 1967 by the Finance Act 2020 and with effect from year of assessment 2020, companies with paid-up capital of RM2.5 million or less, and with annual business income of not more than RM50 million are subject to Small and Medium Enterprise Corporate Tax at 17% on chargeable income up to RM600,000 (2021: RM600,000) except for companies with investment holding nature or companies does not have gross income from business sources are subject to corporate tax at 24% on chargeable income.

0 0 -27823 -31551 -27823 -31551

30678

30866

30678

30866

2855 -685

NOTE 5 – OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES Lease liabilities are measured at present value of the sum of remaining rental payment as of recognition with discount rate of 6.40% per annum adopted from Malayan Banking (Maybank) Berhad's base rate as a reference for discount rate, as this bank is the largest bank and national bank of Malaysia. A single lease cost is recognized over the lease term on a generally straight-line basis. All cash payments of operating lease cost are classified within operating activities in the statement of cash flows. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Operating lease right of use assets as follows:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">As of</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance as of beginning of the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,730</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">41,090</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Add: Addition of lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,281</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less: Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,954</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15,534</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Foreign translation differences</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(341</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,106</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">51,436</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">55,730</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Operating lease liabilities as follows:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance as of beginning of the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56,775</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,909</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Add: Addition of lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,770</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less: gross repayment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,875</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19,618</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Add: imputed interest</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">855</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,913</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign translation differences</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(346</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,199</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance as of end of the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,409</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56,775</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less: lease liability current portion</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,733</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,569</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Lease liability non-current portion</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">35,676</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,206</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The amortization of the right of use asset for the three months’ period ended March 31, 2023 and the three months’ period ended March 31, 2022 were $3,972 and $4,341 respectively. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Other information:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">As of</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Cash paid for amounts included in the measurement of lease liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Operating cash flow from operating lease</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,366</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(126,686</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Right of use assets obtained in exchange for operating lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,436</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,730</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Remaining lease term for operating lease (years)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.75</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average discount rate for operating lease</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.40</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.40</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> Lease expenses for the three months’ period ended March 31, 2023 and the year ended December 31, 2022 were $855 and $4,913, respectively.

0.0640 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Operating lease right of use assets as follows:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">As of</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance as of beginning of the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,730</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">41,090</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Add: Addition of lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,281</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less: Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,954</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15,534</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Foreign translation differences</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(341</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,106</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">51,436</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">55,730</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

55730

41090

0 32281 -3954 -15534 -341 -2106

51436

55730

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Operating lease liabilities as follows:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance as of beginning of the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56,775</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,909</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Add: Addition of lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,770</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less: gross repayment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,875</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19,618</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Add: imputed interest</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">855</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,913</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign translation differences</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(346</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,199</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance as of end of the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,409</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56,775</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less: lease liability current portion</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,733</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,569</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Lease liability non-current portion</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">35,676</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,206</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

56775

42909

0 30770

4875

19618

855 4913 -346 -2199

52409

56775

16733

16569

35676

40206

3972

4341

51436

55730

P3Y9M

P4Y

0.0640 0.0640

855

4913

NOTE 6 - PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consisted of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">As of</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Air conditioner</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,124</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,124</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Computer and software</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,516</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,516</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,525</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,525</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Furniture and fittings</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">87,122</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">87,122</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Lab equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">320,102</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">320,102</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Land and buildings</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,506,969</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,506,969</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Motor vehicle</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">137,914</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">137,914</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Office equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,213</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,213</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Renovation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">107,414</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">107,414</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Signboard</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">806</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">704</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,262,705</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,262,603</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">(Less): Accumulated depreciation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(611,214</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(590,317</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Add: Foreign translation differences</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(169,724</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(133,982</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Property, plant and equipment, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,481,767</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,511,708</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Depreciation expense for the three months’ period ended March 31, 2023 and 2022 were $20,897 and $22,307 respectively.

1124

2516

60525

87122

320102

1506969

137914

38213

107414

806

704

2262705

2262603

611214

590317

-169724 -133982

1481767

1511708

20897

22307

NOTE 7 - OTHER INVESTMENTS <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">As of</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">As of beginning of the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,150,898</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">749,027</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Addition during the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,646</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">511,706</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Disposal during the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,776</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair value loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37,399</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(70,628</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign exchange translation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,268</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(37,431</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">As of end of the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,194,675</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,150,898</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The other investments consist of the following shares: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">As of</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Investment in quoted shares:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Malaysia</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">689,531</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">659,970</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Singapore</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">94,757</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">101,426</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Hong Kong</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">410,387</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">389,502</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,194,675</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,150,898</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">As of</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">As of beginning of the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,150,898</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">749,027</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Addition during the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,646</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">511,706</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Disposal during the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,776</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair value loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37,399</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(70,628</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign exchange translation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,268</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(37,431</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">As of end of the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,194,675</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,150,898</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">As of</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Investment in quoted shares:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Malaysia</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">689,531</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">659,970</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Singapore</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">94,757</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">101,426</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Hong Kong</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">410,387</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">389,502</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,194,675</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,150,898</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 1150898 749027 13646 511706

-1776

37399 -70628 -7268 -37431 1194675 1150898

689531

659970

94757

101426

410387

389502

1194675

1150898

NOTE 8 - TRADE PAYABLES Trade payables are amounts billed to the Company by suppliers for goods and services in the ordinary course of business. All amounts have short-term repayment terms and vary by supplier.

NOTE 9 - CONCENTRATION OF RISKS a) Major customers During the period, the Company did not have any material recognizable major customers accounted for 10% or more of the Company’s revenue for the financial period ended March 31, 2023 and 2022. b) Major suppliers For month ended March 31, 2023 and 2022, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at year ended are presented as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2023</td><td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;">2022</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2023</td><td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2023</td><td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Purchase</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Percentage of purchases</td><td/><td/><td style="BORDER-BOTTOM: #000000 1px solid;"/><td class="hdcell" colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Accounts payable trade</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;">Vendor A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410,208</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">504,906</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.43</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.89</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">408,334</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">502,559</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vendor B</td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">314,739</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,751</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">15.67</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.49</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">313,300</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">332,200</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Vendor C</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">213,965</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">449,494</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">10.65</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">16.82</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">199,312</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">178,749</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">938,912</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1,288,151</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">46.75</td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">48.20</td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">920,946</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1,013,508</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table>

0.10 0.10 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2023</td><td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;">2022</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2023</td><td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2023</td><td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Purchase</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Percentage of purchases</td><td/><td/><td style="BORDER-BOTTOM: #000000 1px solid;"/><td class="hdcell" colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Accounts payable trade</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;">Vendor A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410,208</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">504,906</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.43</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.89</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">408,334</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">502,559</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vendor B</td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">314,739</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,751</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">15.67</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.49</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">313,300</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">332,200</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Vendor C</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">213,965</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">449,494</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">10.65</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">16.82</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">199,312</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">178,749</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">938,912</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1,288,151</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">46.75</td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">48.20</td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">920,946</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1,013,508</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> 410208 504906 0.2043 0.1889 408334 502559 314739 333751 0.1567 0.1249 313300 332200 213965 449494 0.1065 0.1682 199312 178749 938912 1288151 0.4675 0.4820 920946 1013508

NOTE 10 - STOCK HOLDERS’ EQUITY As at March 31, 2023 and 2022, the Company issued and outstanding common stock is 173,718,152 and 171,218,152 shares respectively.

173718152

171218152

NOTE 11 - SEGMENTED INFORMATION At March 31, 2023, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex. <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:70%"><tbody><tr style="height:15px"><td> </td><td> </td><td colspan="2" style="BORDER-TOP: #000000 1px solid; BORDER-RIGHT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> BioNexus Gene Lab Corp.(a Wyoming company) </td><td> </td><td> </td></tr><tr style="height:15px"><td style="width:16%;"> </td><td style="width:17%;"> </td><td style="BORDER-RIGHT: #000000 1px solid;width:17%;"> </td><td style="width:17%;"> </td><td style="width:16%;"> </td><td style="width:17%;"> </td></tr><tr style="height:15px"><td> </td><td> </td><td style="BORDER-RIGHT: #000000 1px solid;"> </td><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td style="BORDER-RIGHT: #000000 1px solid;"> </td><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="BORDER-BOTTOM: #000000 1px solid;"> </td><td style="BORDER-RIGHT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;"> </td><td style="BORDER-BOTTOM: #000000 1px solid;"> </td><td style="BORDER-BOTTOM: #000000 1px solid;"> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="BORDER-LEFT: #000000 1px solid;"> </td><td> </td><td> </td><td style="BORDER-RIGHT: #000000 1px solid;"> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="BORDER-LEFT: #000000 1px solid;"> 100%</td><td> </td><td> </td><td style="BORDER-RIGHT: #000000 1px solid;"> </td><td> 100%</td></tr><tr style="height:15px"><td/><td style="BORDER-LEFT: #000000 1px solid;"/><td> </td><td> </td><td style="BORDER-RIGHT: #000000 1px solid;"/><td/></tr><tr style="height:15px"><td colspan="2" style="BORDER-TOP: #000000 1px solid; BORDER-RIGHT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> Bionexus Gene Lab Sdn Bhd(a Malaysia company) </td><td> </td><td> </td><td colspan="2" style="BORDER-TOP: #000000 1px solid; BORDER-RIGHT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> Chemrex Corporation Sdn Bhd(a Malaysia Company) </td></tr></tbody></table> For the quarter ended March 31, 2023, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">BioNexusMalaysia</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Chemrex</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">BGLC</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three months ended March 31, 2023</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">REVENUE</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,436</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,369,769</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,377,205</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">COST OF REVENUE</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,347</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,002,961</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,008,308 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">GROSS /PROFIT</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,089</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">366,808</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">368,897</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">OTHER INCOME</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,126</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116,218</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">117,344</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">OPERATING EXPENSES</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">General and administrative</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(46,255</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(383,177</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(107,440</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(536,872</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">(LOSS)/PROFIT FROM OPERATIONS</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(43,040</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">99,849</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(107,440</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(50,631</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">FINANCE COSTS</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(666</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,779</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,445</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">(LOSS)/PROFIT BEFORE TAX</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(43,706</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">98,070</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(107,440</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(53,076</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Tax expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,990</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,990</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">NET (LOSS)/PROFIT</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(43,706</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">82,080</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(107,440</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(69,066</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">BioNexusMalaysia</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Chemrex</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">BGLC</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three months ended March 31, 2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">REVENUE</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,269</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,004,676</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,028,945</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">COST OF REVENUE</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,038</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,664,574</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,672,612</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">GROSS PROFIT</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,231</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">340,102</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">356,333</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">OTHER INCOME</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,076</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,306</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46,394</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">OPERATING EXPENSES</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">General and administrative</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(44,042</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(297,769</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(26,225</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(368,036</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">(LOSS)/PROFIT FROM OPERATIONS</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(25,735</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">86,639</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(26,213</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">34,691</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">FINANCE COSTS</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(799</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,527</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,326</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">PROFIT/(LOSS) BEFORE TAX</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(52,269</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">170,751</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(52,426</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31,365</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Tax expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,299</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,299</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">NET PROFIT/(LOSS)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(52,269</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">502,730</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(52,426</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">17,066</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">As of March 31, 2023 and December 31, 2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total Assets</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Total Liabilities</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">BGLC & Bionexus</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">509,574</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">677,477</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,034</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">108,390</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Chemrex</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,677,067</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,062,685</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,536,699</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,966,759</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">TOTAL</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,186,641</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,740,162</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,629,733</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,075,149</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">BioNexusMalaysia</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Chemrex</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">BGLC</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three months ended March 31, 2023</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">REVENUE</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,436</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,369,769</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,377,205</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">COST OF REVENUE</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,347</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,002,961</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,008,308 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">GROSS /PROFIT</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,089</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">366,808</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">368,897</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">OTHER INCOME</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,126</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116,218</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">117,344</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">OPERATING EXPENSES</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">General and administrative</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(46,255</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(383,177</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(107,440</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(536,872</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">(LOSS)/PROFIT FROM OPERATIONS</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(43,040</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">99,849</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(107,440</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(50,631</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">FINANCE COSTS</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(666</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,779</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,445</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">(LOSS)/PROFIT BEFORE TAX</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(43,706</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">98,070</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(107,440</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(53,076</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Tax expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,990</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,990</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">NET (LOSS)/PROFIT</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(43,706</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">82,080</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(107,440</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(69,066</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">BioNexusMalaysia</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Chemrex</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">BGLC</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three months ended March 31, 2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">REVENUE</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,269</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,004,676</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,028,945</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">COST OF REVENUE</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,038</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,664,574</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,672,612</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">GROSS PROFIT</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,231</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">340,102</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">356,333</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">OTHER INCOME</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,076</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,306</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46,394</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">OPERATING EXPENSES</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">General and administrative</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(44,042</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(297,769</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(26,225</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(368,036</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">(LOSS)/PROFIT FROM OPERATIONS</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(25,735</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">86,639</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(26,213</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">34,691</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">FINANCE COSTS</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(799</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,527</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,326</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">PROFIT/(LOSS) BEFORE TAX</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(52,269</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">170,751</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(52,426</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31,365</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Tax expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,299</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,299</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">NET PROFIT/(LOSS)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(52,269</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">502,730</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(52,426</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">17,066</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">As of March 31, 2023 and December 31, 2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total Assets</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Total Liabilities</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">BGLC & Bionexus</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">509,574</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">677,477</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,034</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">108,390</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Chemrex</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,677,067</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,062,685</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,536,699</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,966,759</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">TOTAL</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,186,641</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,740,162</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,629,733</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,075,149</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

7436

2369769

2377205

5347

2002961

2008308

2089

366808

368897

1126

116218

117344

46255

383177

107440

536872

-43040

99849

-107440

-50631

666

1779

2445

-43706

98070

-107440

-53076

15990

-43706

82080

-107440

-69066

24269

3004676

3028945

8038

2664574

2672612

16231

340102

356333

2076

44306

46394

44042

297769

26225

368036

-25735

86639

-26213

34691

799

2527

3326

-52269

170751

-52426

31365

14299

-52269

502730

-52426

17066

509574

677477

93034

108390

7677067

8062685

1536699

1966759

8186641

8740162

1629733

2075149

NOTE 12 - SUBSEQUENT EVENTS In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred after March 31, 2023 up through May 7, 2023 of these consolidated financial statements.

EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end

XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 96 187 1 false 35 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://bion.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://bion.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://bion.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (Unaudited) Sheet http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (Unaudited) Statements 5 false false R6.htm 000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 000007 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND Sheet http://bion.com/role/OrganizationAndBusinessBackground ORGANIZATION AND BUSINESS BACKGROUND Notes 7 false false R8.htm 000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://bion.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 000009 - Disclosure - TRADE RECEIVABLES Sheet http://bion.com/role/TradeReceivables TRADE RECEIVABLES Notes 9 false false R10.htm 000010 - Disclosure - INCOME TAXES Sheet http://bion.com/role/IncomeTaxes INCOME TAXES Notes 10 false false R11.htm 000011 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES Sheet http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilities OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES Notes 11 false false R12.htm 000012 - Disclosure - PROPERTY PLANT AND EQUIPMENT Sheet http://bion.com/role/PropertyPlantAndEquipment PROPERTY PLANT AND EQUIPMENT Notes 12 false false R13.htm 000013 - Disclosure - OTHER INVESTMENTS Sheet http://bion.com/role/OtherInvestments OTHER INVESTMENTS Notes 13 false false R14.htm 000014 - Disclosure - TRADE PAYABLES Sheet http://bion.com/role/TradePayables TRADE PAYABLES Notes 14 false false R15.htm 000015 - Disclosure - CONCENTRATION OF RISKS Sheet http://bion.com/role/ConcentrationOfRisks CONCENTRATION OF RISKS Notes 15 false false R16.htm 000016 - Disclosure - STOCKHOLDERS EQUITY Sheet http://bion.com/role/StockholdersEquity STOCKHOLDERS EQUITY Notes 16 false false R17.htm 000017 - Disclosure - SEGMENTED INFORMATION Sheet http://bion.com/role/SegmentedInformation SEGMENTED INFORMATION Notes 17 false false R18.htm 000018 - Disclosure - SUBSEQUENT EVENTS Sheet http://bion.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 18 false false R19.htm 000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://bion.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://bion.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 000021 - Disclosure - INCOME TAXES (Tables) Sheet http://bion.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://bion.com/role/IncomeTaxes 21 false false R22.htm 000022 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Tables) Sheet http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesTables OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Tables) Tables http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilities 22 false false R23.htm 000023 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Tables) Sheet http://bion.com/role/PropertyPlantAndEquipmentTables PROPERTY PLANT AND EQUIPMENT (Tables) Tables http://bion.com/role/PropertyPlantAndEquipment 23 false false R24.htm 000024 - Disclosure - OTHER INVESTMENTS (Tables) Sheet http://bion.com/role/OtherInvestmentsTables OTHER INVESTMENTS (Tables) Tables http://bion.com/role/OtherInvestments 24 false false R25.htm 000025 - Disclosure - CONCENTRATION OF RISKS (Tables) Sheet http://bion.com/role/ConcentrationOfRisksTables CONCENTRATION OF RISKS (Tables) Tables http://bion.com/role/ConcentrationOfRisks 25 false false R26.htm 000026 - Disclosure - SEGMENTED INFORMATION (Tables) Sheet http://bion.com/role/SegmentedInformationTables SEGMENTED INFORMATION (Tables) Tables http://bion.com/role/SegmentedInformation 26 false false R27.htm 000027 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative) Sheet http://bion.com/role/OrganizationAndBusinessBackgroundDetailsNarrative ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative) Details http://bion.com/role/OrganizationAndBusinessBackground 27 false false R28.htm 000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://bion.com/role/SummaryOfSignificantAccountingPoliciesTables 28 false false R29.htm 000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Sheet http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Details http://bion.com/role/SummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 000030 - Disclosure - TRADE RECEIVABLES (Details Narrative) Sheet http://bion.com/role/TradeReceivablesDetailsNarrative TRADE RECEIVABLES (Details Narrative) Details http://bion.com/role/TradeReceivables 30 false false R31.htm 000031 - Disclosure - INCOME TAXES (Details) Sheet http://bion.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://bion.com/role/IncomeTaxesTables 31 false false R32.htm 000032 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://bion.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://bion.com/role/IncomeTaxesTables 32 false false R33.htm 000033 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details) Sheet http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details) Details http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesTables 33 false false R34.htm 000034 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 1) Sheet http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1 OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 1) Details http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesTables 34 false false R35.htm 000035 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 3) Sheet http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails3 OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 3) Details http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesTables 35 false false R36.htm 000036 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details Narrative) Sheet http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetailsNarrative OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details Narrative) Details http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesTables 36 false false R37.htm 000037 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Details) Sheet http://bion.com/role/PropertyPlantAndEquipmentDetails PROPERTY PLANT AND EQUIPMENT (Details) Details http://bion.com/role/PropertyPlantAndEquipmentTables 37 false false R38.htm 000038 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Details Narrative) Sheet http://bion.com/role/PropertyPlantAndEquipmentDetailsNarrative PROPERTY PLANT AND EQUIPMENT (Details Narrative) Details http://bion.com/role/PropertyPlantAndEquipmentTables 38 false false R39.htm 000039 - Disclosure - OTHER INVESTMENTS (Details) Sheet http://bion.com/role/OtherInvestmentsDetails OTHER INVESTMENTS (Details) Details http://bion.com/role/OtherInvestmentsTables 39 false false R40.htm 000040 - Disclosure - OTHER INVESTMENTS (Details 1) Sheet http://bion.com/role/OtherInvestmentsDetails1 OTHER INVESTMENTS (Details 1) Details http://bion.com/role/OtherInvestmentsTables 40 false false R41.htm 000041 - Disclosure - CONCENTRATION OF RISKS (Details) Sheet http://bion.com/role/ConcentrationOfRisksDetails CONCENTRATION OF RISKS (Details) Details http://bion.com/role/ConcentrationOfRisksTables 41 false false R42.htm 000042 - Disclosure - CONCENTRATION OF RISKS (Details Narrative) Sheet http://bion.com/role/ConcentrationOfRisksDetailsNarrative CONCENTRATION OF RISKS (Details Narrative) Details http://bion.com/role/ConcentrationOfRisksTables 42 false false R43.htm 000043 - Disclosure - STOCK HOLDERS EQUITY (Details Narrative) Sheet http://bion.com/role/StockHoldersEquityDetailsNarrative STOCK HOLDERS EQUITY (Details Narrative) Details 43 false false R44.htm 000044 - Disclosure - SEGMENTED INFORMATION (Details) Sheet http://bion.com/role/SegmentedInformationDetails SEGMENTED INFORMATION (Details) Details http://bion.com/role/SegmentedInformationTables 44 false false R45.htm 000045 - Disclosure - SEGMENTED INFORMATION (Details 1) Sheet http://bion.com/role/SegmentedInformationDetails1 SEGMENTED INFORMATION (Details 1) Details http://bion.com/role/SegmentedInformationTables 45 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: bion:ConcentrationRiskPercentage, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesOutstanding - bion_10q.htm 1 bion_10q.htm bion-20230331.xsd bion-20230331_cal.xml bion-20230331_def.xml bion-20230331_lab.xml bion-20230331_pre.xml bion_ex311.htm bion_ex312.htm bion_ex321.htm bion_ex322.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bion_10q.htm": { "axisCustom": 0, "axisStandard": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 376, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 96, "dts": { "calculationLink": { "local": [ "bion-20230331_cal.xml" ] }, "definitionLink": { "local": [ "bion-20230331_def.xml" ] }, "inline": { "local": [ "bion_10q.htm" ] }, "labelLink": { "local": [ "bion-20230331_lab.xml" ] }, "presentationLink": { "local": [ "bion-20230331_pre.xml" ] }, "schema": { "local": [ "bion-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 277, "entityCount": 1, "hidden": { "http://bion.com/20230331": 2, "http://fasb.org/us-gaap/2022": 7, "http://xbrl.sec.gov/dei/2022": 5, "total": 14 }, "keyCustom": 40, "keyStandard": 147, "memberCustom": 26, "memberStandard": 9, "nsprefix": "bion", "nsuri": "http://bion.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://bion.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "10", "role": "http://bion.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES", "menuCat": "Notes", "order": "11", "role": "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilities", "shortName": "OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - PROPERTY PLANT AND EQUIPMENT", "menuCat": "Notes", "order": "12", "role": "http://bion.com/role/PropertyPlantAndEquipment", "shortName": "PROPERTY PLANT AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:OtherInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - OTHER INVESTMENTS", "menuCat": "Notes", "order": "13", "role": "http://bion.com/role/OtherInvestments", "shortName": "OTHER INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:OtherInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:TradePayablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - TRADE PAYABLES", "menuCat": "Notes", "order": "14", "role": "http://bion.com/role/TradePayables", "shortName": "TRADE PAYABLES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:TradePayablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - CONCENTRATION OF RISKS", "menuCat": "Notes", "order": "15", "role": "http://bion.com/role/ConcentrationOfRisks", "shortName": "CONCENTRATION OF RISKS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - STOCKHOLDERS EQUITY", "menuCat": "Notes", "order": "16", "role": "http://bion.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - SEGMENTED INFORMATION", "menuCat": "Notes", "order": "17", "role": "http://bion.com/role/SegmentedInformation", "shortName": "SEGMENTED INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "18", "role": "http://bion.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "19", "role": "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://bion.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:ScheduleOfPrincipalAnnualRatesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "20", "role": "http://bion.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:ScheduleOfPrincipalAnnualRatesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "21", "role": "http://bion.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Tables)", "menuCat": "Tables", "order": "22", "role": "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesTables", "shortName": "OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Tables)", "menuCat": "Tables", "order": "23", "role": "http://bion.com/role/PropertyPlantAndEquipmentTables", "shortName": "PROPERTY PLANT AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "bion:OtherInvestmentsTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:OtherInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - OTHER INVESTMENTS (Tables)", "menuCat": "Tables", "order": "24", "role": "http://bion.com/role/OtherInvestmentsTables", "shortName": "OTHER INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "bion:OtherInvestmentsTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:OtherInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:ScheduleofmajorsupplierscostofsalestableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - CONCENTRATION OF RISKS (Tables)", "menuCat": "Tables", "order": "25", "role": "http://bion.com/role/ConcentrationOfRisksTables", "shortName": "CONCENTRATION OF RISKS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:ScheduleofmajorsupplierscostofsalestableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - SEGMENTED INFORMATION (Tables)", "menuCat": "Tables", "order": "26", "role": "http://bion.com/role/SegmentedInformationTables", "shortName": "SEGMENTED INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31_bion_BGSLabSdnBhdMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://bion.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "shortName": "ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31_bion_BGSLabSdnBhdMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bion:ScheduleOfPrincipalAnnualRatesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31_us-gaap_EquipmentMember", "decimals": "INF", "first": true, "lang": null, "name": "bion:PrincipalAnnualRatesExpectedUsefulLife", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "menuCat": "Details", "order": "28", "role": "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bion:ScheduleOfPrincipalAnnualRatesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31_us-gaap_EquipmentMember", "decimals": "INF", "first": true, "lang": null, "name": "bion:PrincipalAnnualRatesExpectedUsefulLife", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bion:ScheduleOfExchangeRatesTableTextBlock", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:YearEndedUsDollorOneMyrExchangeRate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)", "menuCat": "Details", "order": "29", "role": "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails1", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bion:ScheduleOfExchangeRatesTableTextBlock", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bion:YearEndedUsDollorOneMyrExchangeRate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://bion.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:AccountsAndNontradeReceivableTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - TRADE RECEIVABLES (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://bion.com/role/TradeReceivablesDetailsNarrative", "shortName": "TRADE RECEIVABLES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AccountsAndNontradeReceivableTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "bion:TaxRecoverable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - INCOME TAXES (Details)", "menuCat": "Details", "order": "31", "role": "http://bion.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "bion:TaxRecoverable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31_bion_MalaysiasMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://bion.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31_bion_MalaysiasMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details)", "menuCat": "Details", "order": "33", "role": "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails", "shortName": "OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bion:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bion:ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "bion:ForeignTranslationDifferences", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 1)", "menuCat": "Details", "order": "34", "role": "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1", "shortName": "OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bion:ScheduleOfOperatingLeaseLiabilityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2021-12-31_bion_OperatingLeaseLiabilityMember", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bion:ScheduleOfAmortizationOfRightOfUseTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "bion:OperatingCashFlowFromOperatingLease", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 3)", "menuCat": "Details", "order": "35", "role": "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails3", "shortName": "OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bion:ScheduleOfAmortizationOfRightOfUseTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "bion:OperatingCashFlowFromOperatingLease", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetailsNarrative", "shortName": "OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Details)", "menuCat": "Details", "order": "37", "role": "http://bion.com/role/PropertyPlantAndEquipmentDetails", "shortName": "PROPERTY PLANT AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://bion.com/role/PropertyPlantAndEquipmentDetailsNarrative", "shortName": "PROPERTY PLANT AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bion:OtherInvestmentsTableTextBlock", "bion:OtherInvestmentsTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "bion:OtherInvestmentsBeginningBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - OTHER INVESTMENTS (Details)", "menuCat": "Details", "order": "39", "role": "http://bion.com/role/OtherInvestmentsDetails", "shortName": "OTHER INVESTMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bion:OtherInvestmentsTableTextBlock", "bion:OtherInvestmentsTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "bion:OtherInvestmentsBeginningBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - OTHER INVESTMENTS (Details 1)", "menuCat": "Details", "order": "40", "role": "http://bion.com/role/OtherInvestmentsDetails1", "shortName": "OTHER INVESTMENTS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "bion:OtherInvestmentsTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31_bion_MalaysiasMember", "decimals": "0", "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "bion:ScheduleofmajorsupplierscostofsalestableTextblock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "bion:ConcentrationRiskPurchase", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - CONCENTRATION OF RISKS (Details)", "menuCat": "Details", "order": "41", "role": "http://bion.com/role/ConcentrationOfRisksDetails", "shortName": "CONCENTRATION OF RISKS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "bion:ScheduleofmajorsupplierscostofsalestableTextblock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "bion:ConcentrationRiskPurchase", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "bion:ScheduleofmajorsupplierscostofsalestableTextblock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "bion:ConcentrationRiskPercentage", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - CONCENTRATION OF RISKS (Details Narrative)", "menuCat": "Details", "order": "42", "role": "http://bion.com/role/ConcentrationOfRisksDetailsNarrative", "shortName": "CONCENTRATION OF RISKS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31_bion_MajorCustomerMember", "decimals": "INF", "lang": null, "name": "bion:ConcentrationRiskPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - STOCK HOLDERS EQUITY (Details Narrative)", "menuCat": "Details", "order": "43", "role": "http://bion.com/role/StockHoldersEquityDetailsNarrative", "shortName": "STOCK HOLDERS EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - SEGMENTED INFORMATION (Details)", "menuCat": "Details", "order": "44", "role": "http://bion.com/role/SegmentedInformationDetails", "shortName": "SEGMENTED INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:OtherGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000045 - Disclosure - SEGMENTED INFORMATION (Details 1)", "menuCat": "Details", "order": "45", "role": "http://bion.com/role/SegmentedInformationDetails1", "shortName": "SEGMENTED INFORMATION (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2023-03-31_bion_ChemrexMember", "decimals": "0", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "bion:DividendIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND", "menuCat": "Notes", "order": "7", "role": "http://bion.com/role/OrganizationAndBusinessBackground", "shortName": "ORGANIZATION AND BUSINESS BACKGROUND", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://bion.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - TRADE RECEIVABLES", "menuCat": "Notes", "order": "9", "role": "http://bion.com/role/TradeReceivables", "shortName": "TRADE RECEIVABLES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 35, "tag": { "bion_AccumulatedAmortizationOfLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Less: Amortization" } } }, "localname": "AccumulatedAmortizationOfLease", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bion_AddAdditionOfLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Add: Addition of lease liabilities" } } }, "localname": "AddAdditionOfLeaseLiabilities", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "bion_AddForeignTranslationDifferences": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Add: Foreign translation differences" } } }, "localname": "AddForeignTranslationDifferences", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "bion_AddImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Add: imputed interest" } } }, "localname": "AddImputedInterest", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "bion_AdditionDuringTheYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Addition during the year" } } }, "localname": "AdditionDuringTheYear", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "bion_AdditionOfRightOfUseliabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Add;Addition of lease liabilities" } } }, "localname": "AdditionOfRightOfUseliabilities", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bion_AirconditionerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Air Conditioner [Member]" } } }, "localname": "AirconditionerMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bion_BGSLabSdnBhdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BGS Lab Sdn. Bhd [Member]" } } }, "localname": "BGSLabSdnBhdMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "domainItemType" }, "bion_BglcAndBionexusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BGLC & Bionexus [Member]" } } }, "localname": "BglcAndBionexusMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/SegmentedInformationDetails1" ], "xbrltype": "domainItemType" }, "bion_BglcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BGLC [Member]" } } }, "localname": "BglcMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/SegmentedInformationDetails" ], "xbrltype": "domainItemType" }, "bion_BionexusMalaysiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BioNexus Malaysia [Member]" } } }, "localname": "BionexusMalaysiaMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/SegmentedInformationDetails" ], "xbrltype": "domainItemType" }, "bion_BuildingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Buildings [Member]" } } }, "localname": "BuildingsMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bion_CashAndCashEquivalentsEndOfFinancialYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash and cash equivalents, end of financial year" } } }, "localname": "CashAndCashEquivalentsEndOfFinancialYear", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bion_CashAtBank": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash at bank" } } }, "localname": "CashAtBank", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bion_ChemrexCorporationSdnBhdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chemrex Corporation Sdn. Bhd. [Member]" } } }, "localname": "ChemrexCorporationSdnBhdMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "domainItemType" }, "bion_ChemrexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chemrex [Member]" } } }, "localname": "ChemrexMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/SegmentedInformationDetails", "http://bion.com/role/SegmentedInformationDetails1" ], "xbrltype": "domainItemType" }, "bion_ComputerAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Computer and Software [Member]" } } }, "localname": "ComputerAndSoftwareMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bion_ConcentrationOfRiskAccountsPayableTrade": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts payable trade" } } }, "localname": "ConcentrationOfRiskAccountsPayableTrade", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetails" ], "xbrltype": "monetaryItemType" }, "bion_ConcentrationRiskPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of purchases", "verboseLabel": "Concentration of risk of credit risk" } } }, "localname": "ConcentrationRiskPercentage", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetails", "http://bion.com/role/ConcentrationOfRisksDetailsNarrative" ], "xbrltype": "percentItemType" }, "bion_ConcentrationRiskPurchase": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Concentration of risk purchase" } } }, "localname": "ConcentrationRiskPurchase", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetails" ], "xbrltype": "monetaryItemType" }, "bion_DividendIncome": { "auth_ref": [], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after discount, accretion and premium amortization, of interest income and dividend income classified as other.", "label": "[Dividend income]", "negatedLabel": "Dividend income" } } }, "localname": "DividendIncome", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bion_EarningPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per share - Basic and diluted" } } }, "localname": "EarningPerShareBasicAndDiluted", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "bion_FairValueLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fair value loss" } } }, "localname": "FairValueLoss", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "bion_FixedDepositsPlacedWithFinancialInstitutions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Fixed deposits placed with financial institutions]", "verboseLabel": "Fixed deposits placed with financial institutions" } } }, "localname": "FixedDepositsPlacedWithFinancialInstitutions", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bion_ForeignCurrencyTranslationLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Foreign currency translation loss]", "verboseLabel": "Foreign currency translation loss" } } }, "localname": "ForeignCurrencyTranslationLoss", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "bion_ForeignExchangeTranslation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Foreign exchange translation" } } }, "localname": "ForeignExchangeTranslation", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "bion_ForeignTranslationDifferences": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Foreign translation differences", "verboseLabel": "Foreign translation differences" } } }, "localname": "ForeignTranslationDifferences", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails", "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "bion_FurnitureAndFittingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Furniture and fittings [Member]" } } }, "localname": "FurnitureAndFittingsMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "bion_HongKongsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hong Kong [Member]" } } }, "localname": "HongKongsMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OtherInvestmentsDetails1" ], "xbrltype": "domainItemType" }, "bion_IncomeTaxsLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Total]", "verboseLabel": "Total" } } }, "localname": "IncomeTaxsLiability", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bion_IncreaseDecreaseInDeferredCostOfRevenue": { "auth_ref": [], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred cost of revenue" } } }, "localname": "IncreaseDecreaseInDeferredCostOfRevenue", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bion_LabEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lab Equipment [Member]" } } }, "localname": "LabEquipmentMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bion_LandAndBuildingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Land and buildings [Member]" } } }, "localname": "LandAndBuildingsMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "bion_LocalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Local [Member]" } } }, "localname": "LocalMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bion_MajorCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major Customer [Member]" } } }, "localname": "MajorCustomerMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "bion_MajorSuppliersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major Suppliers [Member]" } } }, "localname": "MajorSuppliersMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "bion_MalayanBankingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Malayan Banking [Member]" } } }, "localname": "MalayanBankingMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bion_MalaysiasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Malaysia [Member]" } } }, "localname": "MalaysiasMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/IncomeTaxesDetails", "http://bion.com/role/IncomeTaxesDetailsNarrative", "http://bion.com/role/OtherInvestmentsDetails1" ], "xbrltype": "domainItemType" }, "bion_MotorVehicleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Motor Vehicle [Member]", "verboseLabel": "Motor Vehicle [Member]" } } }, "localname": "MotorVehicleMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bion_OperatingCashFlowFromOperatingLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating cash flow from operating lease" } } }, "localname": "OperatingCashFlowFromOperatingLease", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails3" ], "xbrltype": "monetaryItemType" }, "bion_OperatingLeaseLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating lease liability [Member]" } } }, "localname": "OperatingLeaseLiabilityMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1" ], "xbrltype": "domainItemType" }, "bion_OtherInvestmentsBeginningBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "As of beginning of the year" } } }, "localname": "OtherInvestmentsBeginningBalance", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "bion_OtherInvestmentsEningBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "As of end of the year" } } }, "localname": "OtherInvestmentsEningBalance", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "bion_OtherInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Other Investments" } } }, "localname": "OtherInvestmentsTableTextBlock", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OtherInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "bion_OtherInvestmentsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[OTHER INVESTMENTS]", "verboseLabel": "OTHER INVESTMENTS" } } }, "localname": "OtherInvestmentsTextBlock", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OtherInvestments" ], "xbrltype": "textBlockItemType" }, "bion_PrincipalAnnualRatesExpectedUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Principal Annual Rates" } } }, "localname": "PrincipalAnnualRatesExpectedUsefulLife", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "bion_RelatedPartiesPoliciesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related parties" } } }, "localname": "RelatedPartiesPoliciesTextBlock", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bion_RenovationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Renovation [Member]", "verboseLabel": "Renovation [Member]" } } }, "localname": "RenovationMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bion_RentalDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rental payment discount rate" } } }, "localname": "RentalDiscountRate", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "bion_ScheduleOfAmortizationOfRightOfUseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Amortization of Right of Use" } } }, "localname": "ScheduleOfAmortizationOfRightOfUseTableTextBlock", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "bion_ScheduleOfExchangeRatesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Exchange Rates" } } }, "localname": "ScheduleOfExchangeRatesTableTextBlock", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "bion_ScheduleOfOperatingLeaseLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of the operating lease liability" } } }, "localname": "ScheduleOfOperatingLeaseLiabilityTableTextBlock", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "bion_ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of operating lease right of use assets" } } }, "localname": "ScheduleOfOperatingLeaseRightOfUseAssetsTableTextBlock", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "bion_ScheduleOfPrincipalAnnualRatesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Principal Annual Rates" } } }, "localname": "ScheduleOfPrincipalAnnualRatesTableTextBlock", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "bion_ScheduleofmajorsupplierscostofsalestableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Major suppliers Cost Of Sales" } } }, "localname": "ScheduleofmajorsupplierscostofsalestableTextblock", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/ConcentrationOfRisksTables" ], "xbrltype": "textBlockItemType" }, "bion_SignboardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Signboard [Member]" } } }, "localname": "SignboardMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bion_SingaporesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Singapore [Member]" } } }, "localname": "SingaporesMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OtherInvestmentsDetails1" ], "xbrltype": "domainItemType" }, "bion_TaxRecoverable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Tax Recoverable" } } }, "localname": "TaxRecoverable", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bion_ThreeMonthsAverageUsOneMyrExchangeRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "3 months average US$1: MYR exchange rate" } } }, "localname": "ThreeMonthsAverageUsOneMyrExchangeRate", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "bion_TradePayablesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[TRADE PAYABLES]", "verboseLabel": "TRADE PAYABLES" } } }, "localname": "TradePayablesTextBlock", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/TradePayables" ], "xbrltype": "textBlockItemType" }, "bion_VendorAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vendor A [Member]" } } }, "localname": "VendorAMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetails" ], "xbrltype": "domainItemType" }, "bion_VendorBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vendor B [Member]" } } }, "localname": "VendorBMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetails" ], "xbrltype": "domainItemType" }, "bion_VendorCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vendor C [Member]" } } }, "localname": "VendorCMember", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetails" ], "xbrltype": "domainItemType" }, "bion_WeightedAverageDiscountRateForOperatingLease": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average discount rate for operating lease" } } }, "localname": "WeightedAverageDiscountRateForOperatingLease", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails3" ], "xbrltype": "percentItemType" }, "bion_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding - Basic and diluted" } } }, "localname": "WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "bion_YearEndedUsDollorOneMyrExchangeRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Period ended March 31, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate" } } }, "localname": "YearEndedUsDollorOneMyrExchangeRate", "nsuri": "http://bion.com/20230331", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address Address Line 3" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bion.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r197", "r198", "r199", "r200", "r242", "r303", "r325", "r351", "r352", "r367", "r371", "r375", "r405", "r416", "r417", "r418", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r197", "r198", "r199", "r200", "r242", "r303", "r325", "r351", "r352", "r367", "r371", "r375", "r405", "r416", "r417", "r418", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r197", "r198", "r199", "r200", "r240", "r242", "r243", "r244", "r245", "r302", "r303", "r325", "r351", "r352", "r367", "r371", "r375", "r402", "r405", "r417", "r418", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r197", "r198", "r199", "r200", "r240", "r242", "r243", "r244", "r245", "r302", "r303", "r325", "r351", "r352", "r367", "r371", "r375", "r402", "r405", "r417", "r418", "r419", "r420", "r421" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r184", "r185", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r368", "r374", "r406" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bion.com/role/IncomeTaxesDetails", "http://bion.com/role/IncomeTaxesDetailsNarrative", "http://bion.com/role/OtherInvestmentsDetails1" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r184", "r185", "r336", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r368", "r374", "r406" ], "lang": { "en-us": { "role": { "label": "Statement Geographical Axis" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bion.com/role/IncomeTaxesDetails", "http://bion.com/role/IncomeTaxesDetailsNarrative", "http://bion.com/role/OtherInvestmentsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndNontradeReceivableTextBlock": { "auth_ref": [ "r189", "r192" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable.", "label": "Accounts and Nontrade Receivable [Text Block]", "verboseLabel": "TRADE RECEIVABLES" } } }, "localname": "AccountsAndNontradeReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/TradeReceivables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15", "r373" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Trade payables" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r321", "r337" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Trade receivables" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r56", "r115" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]", "negatedLabel": "Less: Accumulated amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r24", "r25", "r118", "r322", "r330", "r331" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive losses" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r22", "r25", "r77", "r297", "r326", "r327", "r385", "r386", "r387", "r393", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income/(Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH AND CASH EQUIVALENTS INFORMATION:" } } }, "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r10", "r373" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r246", "r247", "r248", "r393", "r394", "r395", "r408" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r390" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of adjustments to net income or loss necessary to remove the effects of all items whose cash effects are investing or financing cash flows. The aggregate amount also includes all noncash expenses and income items which reduce or increase net income and are thus added back or deducted when calculating cash provided by or used in operating activities.", "label": "[Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities]", "totalLabel": "Operating (loss)/profit before working capital changes" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net (loss)/profit to net cash (used in)/generated from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r86", "r96", "r116", "r140", "r170", "r174", "r179", "r190", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r272", "r274", "r280", "r373", "r403", "r404", "r414" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "TOTAL ASSETS", "verboseLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets", "http://bion.com/role/SegmentedInformationDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r111", "r121", "r140", "r190", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r272", "r274", "r280", "r373", "r403", "r404", "r414" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r140", "r190", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r272", "r274", "r280", "r403", "r404", "r414" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "[Assets, Noncurrent]", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CURRENT ASSETS" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r271", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r70", "r71", "r271", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.", "label": "Business acquisition, business operation description" } } }, "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": { "auth_ref": [ "r66", "r67", "r69" ], "lang": { "en-us": { "role": { "documentation": "Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format.", "label": "Business Acquisition, Effective Date of Acquisition" } } }, "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business aquisition, shares converted" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_Cash": { "auth_ref": [ "r334", "r335", "r373", "r381" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and bank balances" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r34", "r39", "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF FINANCIAL YEAR", "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL YEAR" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r34", "r83" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]", "totalLabel": "NET CHANGE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CollateralAxis": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Information by category of collateral or no collateral, from lender's perspective.", "label": "Collateral Axis" } } }, "localname": "CollateralAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of collateral or no collateral, from lender's perspective." } } }, "localname": "CollateralDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r393", "r394", "r408" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/StockHoldersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r9", "r60" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://bion.com/role/StockHoldersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r9", "r373" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "As at March 31, 2023, common stock, no par value; 300,000,000 shares authorized and 173,718,152 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2022, common stock, no par value; 300,000,000 shares authorized and 173,718,152 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r26", "r123", "r125", "r132", "r318", "r323" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "[Comprehensive Income (Loss), Net of Tax, Attributable to Parent]", "totalLabel": "COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r46", "r47", "r81", "r82", "r187", "r338", "r422" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type Axis" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "verboseLabel": "CONCENTRATION OF RISKS" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/ConcentrationOfRisks" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r46", "r47", "r81", "r82", "r187", "r338" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r75", "r355" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Basis of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r30", "r140", "r190", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r280", "r403" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "[Cost of Revenue]", "negatedLabel": "COST OF REVENUE" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://bion.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerAdvancesCurrent": { "auth_ref": [ "r106" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current portion of prepayments received from customers for goods or services to be provided in the future.", "label": "Advance payment from customer" } } }, "localname": "CustomerAdvancesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r4", "r5", "r6", "r87", "r89", "r95", "r143", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r290", "r362", "r363", "r364", "r365", "r366", "r391" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument Axis" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Non-interest bearing" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/TradeReceivablesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r20", "r143", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r290", "r362", "r363", "r364", "r365", "r366", "r391" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r251", "r252" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r64", "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "[Deferred Tax Liabilities, Net]", "verboseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssets": { "auth_ref": [ "r383" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.", "label": "Fixed deposits placed with financial institutions" } } }, "localname": "DepositsAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r37", "r54" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation of property, plant and equipment", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://bion.com/role/PropertyPlantAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r196", "r390", "r401" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal during the year" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r44", "r45" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net earnings or loss per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r281" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 22.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Foreign currency translation adjustment" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r141", "r254", "r265" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r60", "r109", "r127", "r128", "r129", "r144", "r145", "r146", "r148", "r153", "r155", "r158", "r191", "r239", "r246", "r247", "r248", "r261", "r262", "r277", "r282", "r283", "r284", "r285", "r286", "r287", "r297", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r279" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.", "label": "[Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)]", "negatedLabel": "Fair value loss/(gain) on other investments" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair value of financial instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Remaining lease term for operating lease (years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails3" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign currencies translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fittings [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfOtherInvestments": { "auth_ref": [ "r37" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) included in earnings for investments classified as other.", "label": "[Gain (Loss) on Sale of Other Investments]", "negatedLabel": "Gain on disposal of other investments" } } }, "localname": "GainLossOnSaleOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r31" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "[General and Administrative Expense]", "negatedLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r29", "r140", "r170", "r173", "r178", "r181", "r190", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r280", "r360", "r403" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "GROSS PROFIT", "verboseLabel": "GROSS PROFIT" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://bion.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r53", "r58" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r27", "r85", "r92", "r104", "r170", "r173", "r178", "r181", "r319", "r360" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]", "totalLabel": "(LOSS)/PROFIT BEFORE TAX", "verboseLabel": "(LOSS)/PROFIT BEFORE TAX" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://bion.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r141", "r255", "r256", "r259", "r263", "r266", "r268", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r142", "r154", "r155", "r169", "r253", "r264", "r267", "r324" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "[Income Tax Expense (Benefit)]", "negatedLabel": "Tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://bion.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r126", "r249", "r250", "r256", "r257", "r258", "r260" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r91", "r102", "r384" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Tax recoverable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "auth_ref": [ "r36" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.", "label": "[Increase (Decrease) in Accounts and Other Receivables]", "negatedLabel": "Trade and other receivables" } } }, "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCustomerAdvances": { "auth_ref": [ "r107" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of prepayments by customers for goods or services to be provided at a later date.", "label": "[Increase (Decrease) in Customer Advances]", "verboseLabel": "Advance payment from customer" } } }, "localname": "IncreaseDecreaseInCustomerAdvances", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r354" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "auth_ref": [ "r36" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "[Increase (Decrease) in Income Taxes Receivable]", "negatedLabel": "Tax recoverable" } } }, "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r36" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Inventories]", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r389", "r411" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayable": { "auth_ref": [ "r36" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Trade and other payables" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r84", "r94", "r130", "r168", "r289" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "FINANCE COSTS", "verboseLabel": "FINANCE COSTS" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://bion.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r133", "r136", "r137" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "[Interest Paid, Excluding Capitalized Interest, Operating Activities]", "negatedLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r120", "r353", "r373" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r113", "r119", "r157", "r193", "r194", "r195", "r304", "r356" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INVESTMENTS" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "verboseLabel": "OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r16", "r140", "r190", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r273", "r274", "r275", "r280", "r359", "r403", "r414", "r415" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "TOTAL LIABILITIES", "verboseLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets", "http://bion.com/role/SegmentedInformationDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r14", "r90", "r99", "r373", "r392", "r400", "r409" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r18", "r112", "r140", "r190", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r273", "r274", "r275", "r280", "r373", "r403", "r414", "r415" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r1", "r2", "r3", "r6", "r7", "r140", "r190", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r273", "r274", "r275", "r280", "r403", "r414", "r415" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "[Liabilities, Noncurrent]", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CURRENT LIABILITIES" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r135" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r34", "r35", "r38" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r28", "r38", "r93", "r103", "r110", "r122", "r124", "r129", "r140", "r147", "r149", "r150", "r151", "r152", "r154", "r155", "r156", "r170", "r173", "r178", "r181", "r190", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r278", "r280", "r360", "r403" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 12.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net (loss)/profit", "totalLabel": "NET (LOSS)/PROFIT", "verboseLabel": "Net profit for the period" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://bion.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r170", "r173", "r178", "r181", "r360" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "(LOSS)/PROFIT FROM OPERATIONS", "verboseLabel": "(LOSS)/PROFIT FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://bion.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r410" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Lease expenses" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "[Operating Lease, Liability]", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r292" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r292" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Non-current portion of operating lease liabilities", "verboseLabel": "Lease liabilities non-current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets", "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r293", "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "[Operating Lease, Payments]", "negatedLabel": "Less: gross repayment" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r291" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right of use assets", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets", "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r390" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of right of use asset", "verboseLabel": "Amortization of right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND BUSINESS BACKGROUND" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r78" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "ORGANIZATION AND BUSINESS BACKGROUND" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OrganizationAndBusinessBackground" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.", "label": "Other payables and accrued liabilities" } } }, "localname": "OtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r73", "r74", "r76" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 11.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Foreign currency translation loss" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "[Other General and Administrative Expense]", "negatedLabel": "General and administrative" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r105" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "OTHER INCOME", "verboseLabel": "OTHER INCOME" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://bion.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestments": { "auth_ref": [ "r101", "r382" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments classified as other.", "label": "Other investments", "verboseLabel": "Other investment" } } }, "localname": "OtherInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets", "http://bion.com/role/OtherInvestmentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r17", "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "[Other Liabilities, Current]", "negatedLabel": "Less: lease liabilities current portion" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r117" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other receivables, deposits and prepayments" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TRADE PAYABLES" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r33" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "[Payments to Acquire Other Investments]", "negatedLabel": "Acquisition of other investment" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r32" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "[Payments to Acquire Property, Plant, and Equipment]", "negatedLabel": "Purchase of plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r8", "r226" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "auth_ref": [ "r134", "r388" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.", "label": "[Proceeds from Equity Method Investment, Distribution, Return of Capital]", "verboseLabel": "Dividend income" } } }, "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PROPERTY PLANT AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type Axis" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r59", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY, PLANT AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r55", "r114" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Total Plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r57", "r100", "r320", "r373" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant and equipment, net", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets", "http://bion.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r57", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TRADE RECEIVABLES" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r396", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "verboseLabel": "Trade receivables" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r241", "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r108", "r298", "r299", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetailsNarrative", "http://bion.com/role/SegmentedInformationDetails", "http://bion.com/role/SegmentedInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetailsNarrative", "http://bion.com/role/SegmentedInformationDetails", "http://bion.com/role/SegmentedInformationDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r241", "r298", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party Axis" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r11", "r61", "r98", "r329", "r331", "r373" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated surplus" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r109", "r144", "r145", "r146", "r148", "r153", "r155", "r191", "r246", "r247", "r248", "r261", "r262", "r277", "r326", "r328" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Surplus/(Loss)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r131", "r140", "r166", "r167", "r172", "r176", "r177", "r183", "r184", "r187", "r190", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r280", "r319", "r403" ], "calculation": { "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "REVENUE", "verboseLabel": "REVENUE" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://bion.com/role/SegmentedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r296", "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right of use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONCENTRATION OF RISKS" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Segmented Revenue and Net Profit/(Loss)" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SegmentedInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEGMENTED INFORMATION" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r163", "r164", "r165", "r170", "r171", "r175", "r179", "r180", "r181", "r182", "r183", "r186", "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "SEGMENTED INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SegmentedInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShippingAndHandlingCostPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.", "label": "Shipping and handling fees" } } }, "localname": "ShippingAndHandlingCostPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermDebtInterestRateIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument.", "label": "Interest rate" } } }, "localname": "ShortTermDebtInterestRateIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/TradeReceivablesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r43", "r138" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r21", "r60", "r109", "r127", "r128", "r129", "r144", "r145", "r146", "r148", "r153", "r155", "r158", "r191", "r239", "r246", "r247", "r248", "r261", "r262", "r277", "r282", "r283", "r284", "r285", "r286", "r287", "r297", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetails", "http://bion.com/role/ConcentrationOfRisksDetailsNarrative", "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "http://bion.com/role/IncomeTaxesDetails", "http://bion.com/role/IncomeTaxesDetailsNarrative", "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1", "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetailsNarrative", "http://bion.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "http://bion.com/role/OtherInvestmentsDetails1", "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SegmentedInformationDetails", "http://bion.com/role/SegmentedInformationDetails1", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r144", "r145", "r146", "r158", "r305" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/ConcentrationOfRisksDetails", "http://bion.com/role/ConcentrationOfRisksDetailsNarrative", "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "http://bion.com/role/IncomeTaxesDetails", "http://bion.com/role/IncomeTaxesDetailsNarrative", "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetails1", "http://bion.com/role/OperatingLeaseRightOfUseAssetAndLeaseLiabilitiesDetailsNarrative", "http://bion.com/role/OrganizationAndBusinessBackgroundDetailsNarrative", "http://bion.com/role/OtherInvestmentsDetails1", "http://bion.com/role/PropertyPlantAndEquipmentDetails", "http://bion.com/role/SegmentedInformationDetails", "http://bion.com/role/SegmentedInformationDetails1", "http://bion.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatutoryAccountingPracticesDescriptionOfPermittedPractice": { "auth_ref": [ "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "Description of items listed to reconcile the differences as of the balance sheet date resulting from applying state permitted statutory accounting practices rather than statutory accounting practices permitted by National Association of Insurance Commissioners.", "label": "Statutory income tax rate, description" } } }, "localname": "StatutoryAccountingPracticesDescriptionOfPermittedPractice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r9", "r12", "r13", "r52", "r373", "r392", "r400", "r409" ], "calculation": { "http://bion.com/role/CondensedConsolidatedBalanceSheets": { "order": 26.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets", "http://bion.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS EQUITY" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r62", "r139", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r276" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplementary cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrentAndNoncurrent": { "auth_ref": [ "r5", "r88", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.", "label": "Income tax liabilities" } } }, "localname": "TaxesPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r48", "r49", "r50", "r159", "r160", "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f,g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "310", "URI": "https://asc.fasb.org/topic&trid=2196771", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "326", "URI": "https://asc.fasb.org/topic&trid=82887179", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24746-158529", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24779-158529", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r376": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r377": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r378": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r379": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e845-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e848-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 64 0001477932-23-003193-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-23-003193-xbrl.zip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end

1.	I have reviewed this Quarterly Report on Form 10-Q of the Registrant for the fiscal quarter ended March 31, 2023;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.